UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________________________
FORM 10-Q
____________________________________________________________________________________________ | | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 20222023
or | | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ______ to ______
Commission File Number: 001-37854
____________________________________________________________________________________________
Ekso Bionics Holdings, Inc.
(Exact name of registrant as specified in its charter)
____________________________________________________________________________________________ | | | | | | | | |
Nevada | | 99-0367049 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| | | | | | | | |
1414 Harbour Way South,101 Glacier Point, Suite 1201A
Richmond,San Rafael, CA
| | 9480494901 |
(Address of principal executive offices) | | (Zip Code) |
(510) 984-1761
(Registrant’s telephone number, including area code)
(Former name, former address, and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered: | | | | | | | | | | | | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, $0.001 par value per share | | EKSO | | Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. | | | | | | | | | | | | | | |
Large accelerated filer | ☐ | | Accelerated filer | ☐ |
| | | | |
Non-accelerated filer | ☒ | | Smaller reporting company | ☒ |
| | | | |
| | | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
The number of shares of registrant’s common stock outstanding as of April 25, 20222023 was 12,844,501.13,502,873.
Ekso Bionics Holdings, Inc.
Quarterly Report on Form 10-Q
Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except par value)
| | | March 31, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
| | (unaudited) | | (Note 2) | | (unaudited) | | (Note 2) |
Assets | Assets | | | | Assets | | | |
Current assets: | Current assets: | | | | Current assets: | | | |
Cash | $ | 36,176 | | | $ | 40,406 | | |
Accounts receivable, net of allowances of $19 and $28, respectively | 3,346 | | | 4,662 | | |
Cash and cash equivalents | | Cash and cash equivalents | $ | 16,277 | | | $ | 20,525 | |
Accounts receivable, net of allowances of $11 and $40, respectively | | Accounts receivable, net of allowances of $11 and $40, respectively | 4,827 | | | 4,625 | |
Inventories | Inventories | 2,772 | | | 2,242 | | Inventories | 5,662 | | | 5,187 | |
Prepaid expenses and other current assets | Prepaid expenses and other current assets | 829 | | | 485 | | Prepaid expenses and other current assets | 831 | | | 700 | |
Total current assets | Total current assets | 43,123 | | | 47,795 | | Total current assets | 27,597 | | | 31,037 | |
Property and equipment, net | Property and equipment, net | 886 | | | 991 | | Property and equipment, net | 2,454 | | | 2,680 | |
Right-of-use assets | Right-of-use assets | 92 | | | 216 | | Right-of-use assets | 1,228 | | | 1,307 | |
Intangible assets, net | | Intangible assets, net | 5,136 | | | 5,217 | |
Goodwill | | Goodwill | 431 | | | 431 | |
Other assets | Other assets | 141 | | | 164 | | Other assets | 258 | | | 231 | |
Total assets | Total assets | $ | 44,242 | | | $ | 49,166 | | Total assets | $ | 37,104 | | | $ | 40,903 | |
| Liabilities and Stockholders’ Equity | Liabilities and Stockholders’ Equity | | | | Liabilities and Stockholders’ Equity | |
Current liabilities: | Current liabilities: | | Current liabilities: | |
Accounts payable | Accounts payable | $ | 2,939 | | | $ | 3,107 | | Accounts payable | $ | 3,042 | | | $ | 3,151 | |
Accrued liabilities | Accrued liabilities | 1,819 | | | 2,299 | | Accrued liabilities | 2,227 | | | 2,278 | |
Deferred revenues, current | Deferred revenues, current | 1,115 | | | 1,220 | | Deferred revenues, current | 1,296 | | | 1,121 | |
| Notes payable, current | | Notes payable, current | 2,623 | | | 2,310 | |
Lease liabilities, current | Lease liabilities, current | 97 | | | 229 | | Lease liabilities, current | 349 | | | 341 | |
Total current liabilities | Total current liabilities | 5,970 | | | 6,855 | | Total current liabilities | 9,537 | | | 9,201 | |
Deferred revenues | Deferred revenues | 1,082 | | | 1,475 | | Deferred revenues | 1,367 | | | 1,032 | |
Notes payable, net | Notes payable, net | 1,994 | | | 1,993 | | Notes payable, net | 3,534 | | | 3,767 | |
| Lease liabilities | | Lease liabilities | 999 | | | 1,087 | |
Warrant liabilities | Warrant liabilities | 1,650 | | | 1,550 | | Warrant liabilities | 259 | | | 233 | |
Other non-current liabilities | Other non-current liabilities | 60 | | | 74 | | Other non-current liabilities | 125 | | | 141 | |
Total liabilities | Total liabilities | 10,756 | | | 11,947 | | Total liabilities | 15,821 | | | 15,461 | |
Commitments and contingencies (Note 13) | 0 | | 0 | |
Commitments and contingencies (Note 15) | | Commitments and contingencies (Note 15) | | | |
Stockholders’ equity: | Stockholders’ equity: | | Stockholders’ equity: | |
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at March 31, 2022 and December 31, 2021 | — | | | — | | |
Common stock, $0.001 par value; 141,429 shares authorized; 12,844 and 12,693 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 13 | | | 13 | | |
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at March 31, 2023 and December 31, 2022 | | Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at March 31, 2023 and December 31, 2022 | — | | | — | |
Common stock, $0.001 par value; 141,429 shares authorized; 13,342 and 13,203 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | | Common stock, $0.001 par value; 141,429 shares authorized; 13,342 and 13,203 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 13 | | | 13 | |
Additional paid-in capital | Additional paid-in capital | 246,765 | | | 246,090 | | Additional paid-in capital | 249,237 | | | 248,813 | |
Accumulated other comprehensive gain (loss) | 195 | | | (17) | | |
Accumulated other comprehensive income | | Accumulated other comprehensive income | 369 | | | 563 | |
Accumulated deficit | Accumulated deficit | (213,487) | | | (208,867) | | Accumulated deficit | (228,336) | | | (223,947) | |
Total stockholders’ equity | Total stockholders’ equity | 33,486 | | | 37,219 | | Total stockholders’ equity | 21,283 | | | 25,442 | |
Total liabilities and stockholders’ equity | Total liabilities and stockholders’ equity | $ | 44,242 | | | $ | 49,166 | | Total liabilities and stockholders’ equity | $ | 37,104 | | | $ | 40,903 | |
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
| | | | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| | | | 2022 | | 2021 | | 2023 | | 2022 | |
Revenue | Revenue | | | $ | 2,567 | | | $ | 1,910 | | Revenue | $ | 4,122 | | | $ | 2,567 | | |
Cost of revenue | Cost of revenue | | | 1,358 | | | 675 | | Cost of revenue | 2,122 | | | 1,358 | | |
Gross profit | Gross profit | | | 1,209 | | | 1,235 | | Gross profit | 2,000 | | | 1,209 | | |
| Operating expenses: | Operating expenses: | | | Operating expenses: | | |
Sales and marketing | Sales and marketing | | | 1,629 | | | 1,793 | | Sales and marketing | 2,088 | | | 1,629 | | |
Research and development | Research and development | | | 999 | | | 603 | | Research and development | 1,154 | | | 921 | | |
General and administrative | General and administrative | | | 2,818 | | | 1,978 | | General and administrative | 3,206 | | | 2,896 | | |
| Total operating expenses | Total operating expenses | | | 5,446 | | | 4,374 | | Total operating expenses | 6,448 | | | 5,446 | | |
| Loss from operations | Loss from operations | | | (4,237) | | | (3,139) | | Loss from operations | (4,448) | | | (4,237) | | |
| Other expense, net: | | | |
Other (expense) income, net: | | Other (expense) income, net: | | |
Interest expense | Interest expense | | | (27) | | | (26) | | Interest expense | (127) | | | (27) | | |
(Loss) gain on revaluation of warrant liabilities | | | (100) | | | 11 | | |
Loss on revaluation of warrant liabilities | | Loss on revaluation of warrant liabilities | (26) | | | (100) | | |
| Unrealized gain (loss) on foreign exchange | | Unrealized gain (loss) on foreign exchange | 217 | | | (254) | | |
Other expense, net | Other expense, net | | | (256) | | | (516) | | Other expense, net | (5) | | | (2) | | |
Total other expense, net | | | (383) | | | (531) | | |
Total other income (expense), net | | Total other income (expense), net | 59 | | | (383) | | |
| Net loss | Net loss | | | $ | (4,620) | | | $ | (3,670) | | Net loss | $ | (4,389) | | | $ | (4,620) | | |
Other comprehensive income | | | 212 | | | 465 | | |
Other comprehensive (loss) income | | Other comprehensive (loss) income | (194) | | | 212 | | |
Comprehensive loss | Comprehensive loss | | | $ | (4,408) | | | $ | (3,205) | | Comprehensive loss | $ | (4,583) | | | $ | (4,408) | | |
| Net loss per share applicable to common shareholders, basic and diluted | Net loss per share applicable to common shareholders, basic and diluted | | | $ | (0.36) | | | $ | (0.34) | | Net loss per share applicable to common shareholders, basic and diluted | $ | (0.33) | | | $ | (0.36) | | |
| Weighted average number of shares outstanding, basic and diluted | Weighted average number of shares outstanding, basic and diluted | | | 12,728 | | | 10,752 | | Weighted average number of shares outstanding, basic and diluted | 13,296 | | | 12,728 | | |
| |
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands)
(Unaudited) | | | Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive (Loss) Income | | Accumulated Deficit | | Total Stockholders’ Equity | | Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive (Loss) Income | | Accumulated Deficit | | Total Stockholders’ Equity |
| | Shares | | Amount | | Shares | | Amount | | | Shares | | Amount | | Shares | | Amount | |
Balance at December 31, 2021 | — | | | $ | — | | | 12,693 | | | $ | 13 | | | $ | 246,090 | | | $ | (17) | | | $ | (208,867) | | | $ | 37,219 | | |
Balance at December 31, 2022 | | Balance at December 31, 2022 | — | | | $ | — | | | 13,203 | | | $ | 13 | | | $ | 248,813 | | | $ | 563 | | | $ | (223,947) | | | $ | 25,442 | |
Net loss | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | (4,620) | | | (4,620) | | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | (4,389) | | | (4,389) | |
Issuance of common stock under: | Issuance of common stock under: | | Issuance of common stock under: | |
Matching contribution to 401(k) plan | — | | | — | | | 68 | | | — | | | 176 | | | — | | | — | | | 176 | | |
Equity incentive plan | Equity incentive plan | — | | | — | | | 83 | | | — | | | — | | | — | | | — | | | — | | Equity incentive plan | — | | | — | | | 139 | | | — | | | — | | | — | | | — | | | — | |
| Stock-based compensation expense | Stock-based compensation expense | — | | | — | | | — | | | — | | | 499 | | | — | | | — | | | 499 | | Stock-based compensation expense | — | | | — | | | — | | | — | | | 424 | | | — | | | — | | | 424 | |
Foreign currency translation adjustments | Foreign currency translation adjustments | — | | | — | | | — | | | — | | | — | | | 212 | | | — | | | 212 | | Foreign currency translation adjustments | — | | | — | | | — | | | — | | | — | | | (194) | | | — | | | (194) | |
Balance at March 31, 2022 | — | | | $ | — | | | 12,844 | | | $ | 13 | | | $ | 246,765 | | | $ | 195 | | | $ | (213,487) | | | $ | 33,486 | | |
Balance at March 31, 2023 | | Balance at March 31, 2023 | — | | | $ | — | | | 13,342 | | | $ | 13 | | | $ | 249,237 | | | $ | 369 | | | $ | (228,336) | | | $ | 21,283 | |
| |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive (Loss) Income | | Accumulated Deficit | | Total Stockholders’ Equity |
| Shares | | Amount | | Shares | | Amount | | | | |
Balance at December 31, 2020 | — | | | $ | — | | | 8,349 | | | $ | 8 | | | $ | 204,376 | | | $ | (847) | | | $ | (199,103) | | | $ | 4,434 | |
Net loss | — | | | — | | | — | | | — | | | — | | | — | | | (3,670) | | | (3,670) | |
Issuance of common stock under: | | | | | | | | | | | | | | | |
Equity financing, net | — | | | — | | | 3,980 | | | 4 | | | 35,356 | | | — | | | — | | | 35,360 | |
Exercise of warrants | — | | | — | | | 300 | | | 1 | | | 3,877 | | | — | | | — | | | 3,878 | |
Matching contribution to 401(k) plan | — | | | — | | | 26 | | | — | | | 152 | | | — | | | — | | | 152 | |
Stock-based compensation expense | — | | | — | | | — | | | — | | | 356 | | | — | | | — | | | 356 | |
Foreign currency translation adjustments | — | | | — | | | — | | | — | | | — | | | 465 | | | — | | | 465 | |
Balance at March 31, 2021 | — | | | $ | — | | | 12,655 | | | $ | 13 | | | $ | 244,117 | | | $ | (382) | | | $ | (202,773) | | | $ | 40,975 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive (Loss) Income | | Accumulated Deficit | | Total Stockholders’ Equity |
| Shares | | Amount | | Shares | | Amount | | | | |
Balance at December 31, 2021 | — | | | $ | — | | | 12,693 | | | $ | 13 | | | $ | 246,090 | | | $ | (17) | | | $ | (208,867) | | | $ | 37,219 | |
Net loss | — | | | — | | | — | | | — | | | — | | | — | | | (4,620) | | | (4,620) | |
Issuance of common stock under: | | | | | | | | | | | | | | | |
Matching contribution to 401(k) plan | — | | | — | | | 68 | | | — | | | 176 | | | — | | | — | | | 176 | |
Equity incentive plan | — | | | — | | | 83 | | | — | | | — | | | — | | | — | | | — | |
| | | | | | | | | | | | | | | |
Stock-based compensation expense | — | | | — | | | — | | | — | | | 499 | | | — | | | — | | | 499 | |
Foreign currency translation adjustments | — | | | — | | | — | | | — | | | — | | | 212 | | | — | | | 212 | |
Balance at March 31, 2022 | — | | | $ | — | | | 12,844 | | | $ | 13 | | | $ | 246,765 | | | $ | 195 | | | $ | (213,487) | | | $ | 33,486 | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited) | | | Three Months Ended March 31, | | Three Months Ended March 31, |
| | 2022 | | 2021 | | 2023 | | 2022 |
Operating activities: | Operating activities: | | | | Operating activities: | | | |
Net loss | Net loss | $ | (4,620) | | | $ | (3,670) | | Net loss | $ | (4,389) | | | $ | (4,620) | |
Adjustments to reconcile net loss to net cash used in operating activities | Adjustments to reconcile net loss to net cash used in operating activities | | Adjustments to reconcile net loss to net cash used in operating activities | |
Depreciation | 131 | | | 126 | | |
Depreciation and amortization | | Depreciation and amortization | 414 | | | 231 | |
Changes in allowance for doubtful accounts | Changes in allowance for doubtful accounts | (9) | | | 31 | | Changes in allowance for doubtful accounts | 1 | | | (9) | |
| Loss (gain) on revaluation of warrant liabilities | 100 | | | (11) | | |
Loss on revaluation of warrant liabilities | | Loss on revaluation of warrant liabilities | 26 | | | 100 | |
| Stock-based compensation expense | Stock-based compensation expense | 499 | | | 356 | | Stock-based compensation expense | 424 | | | 499 | |
Common stock contribution to 401(k) plan | Common stock contribution to 401(k) plan | 64 | | | 52 | | Common stock contribution to 401(k) plan | 93 | | | 64 | |
| Unrealized loss on foreign currency transactions | 254 | | | 503 | | |
Unrealized (gain) loss on foreign currency transactions | | Unrealized (gain) loss on foreign currency transactions | (217) | | | 254 | |
Changes in operating assets and liabilities: | Changes in operating assets and liabilities: | | Changes in operating assets and liabilities: | |
Accounts receivable | Accounts receivable | 1,297 | | | 917 | | Accounts receivable | (202) | | | 1,297 | |
Inventories | Inventories | (562) | | | (228) | | Inventories | (375) | | | (562) | |
Prepaid expenses, right-of-use assets, and other assets | (203) | | | (78) | | |
Prepaid expenses and other assets, current and noncurrent | | Prepaid expenses and other assets, current and noncurrent | (134) | | | (302) | |
Accounts payable | Accounts payable | (166) | | | 151 | | Accounts payable | (110) | | | (166) | |
Accrued, lease and other liabilities | (503) | | | 16 | | |
Accrued, lease and other liabilities, current and noncurrent | | Accrued, lease and other liabilities, current and noncurrent | (248) | | | (504) | |
Deferred revenues | Deferred revenues | (488) | | | (165) | | Deferred revenues | 503 | | | (488) | |
Net cash used in operating activities | Net cash used in operating activities | (4,206) | | | (2,000) | | Net cash used in operating activities | (4,214) | | | (4,206) | |
Investing activities: | | Investing activities: | | | |
Acquisition of property and equipment | | Acquisition of property and equipment | (42) | | | — | |
Net cash used in investing activities | | Net cash used in investing activities | (42) | | | — | |
| Financing activities: | | | | |
Proceeds from issuance of common stock and warrants, net | — | | | 37,295 | | |
| Proceeds from exercise of warrants | — | | | 1,417 | | |
Net cash provided by financing activities | — | | | 38,712 | | |
| Effect of exchange rate changes on cash | Effect of exchange rate changes on cash | (24) | | | (35) | | Effect of exchange rate changes on cash | 8 | | | (24) | |
Net (decrease) increase in cash | (4,230) | | | 36,677 | | |
Net decrease in cash | | Net decrease in cash | (4,248) | | | (4,230) | |
Cash at beginning of period | Cash at beginning of period | 40,406 | | | 12,862 | | Cash at beginning of period | 20,525 | | | 40,406 | |
Cash at end of period | Cash at end of period | $ | 36,176 | | | $ | 49,539 | | Cash at end of period | $ | 16,277 | | | $ | 36,176 | |
| Supplemental disclosure of cash flow activities | Supplemental disclosure of cash flow activities | | Supplemental disclosure of cash flow activities | |
Cash paid for interest | Cash paid for interest | $ | 27 | | | $ | 23 | | Cash paid for interest | $ | 47 | | | $ | 27 | |
| | Supplemental disclosure of non-cash activities | Supplemental disclosure of non-cash activities | | Supplemental disclosure of non-cash activities | |
Fair value of warrants issued upon equity financing | $ | — | | | $ | 1,936 | | |
Reclassification of warrant liability to equity upon exercise of warrants | $ | — | | | $ | 2,461 | | |
Transfer of inventory to (from) property and equipment | $ | 29 | | | $ | 53 | | |
| Transfer of inventory (from) to property and equipment | | Transfer of inventory (from) to property and equipment | $ | (96) | | | $ | 29 | |
| Share issuance for common stock contribution to 401(k) plan | Share issuance for common stock contribution to 401(k) plan | $ | 176 | | | $ | 152 | | Share issuance for common stock contribution to 401(k) plan | $ | — | | | $ | 176 | |
|
The accompanying notes are an integral part of these condensed consolidated financial statements
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
1. Organization
Description of Business
Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and by persons with physical disabilities. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI"), to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol “EKSO”.
On December 5, 2022, the Company acquired the Human Motion and Control (“HMC”) Business Unit from Parker Hannifin Corporation (“Parker”), an Ohio corporation. The assets acquired from the business unit include intellectual property rights for devices which are U.S. Food and Drug Administration ("FDA")-cleared lower-limb powered exoskeletons that enable task-specific, overground gait training to patients with weakness or paralysis in their lower extremities. Products include Ekso Indego Personal, a light-weight exoskeleton for safe use in most home and community environments, and Ekso Indego Therapy, an adjustable exoskeleton for patients with spinal cord injury and stroke, complementing Ekso’s product offering in outpatient facilities.
Liquidity and Capital Resources
As of March 31, 2022,2023, the Company had an accumulated deficit of $213,487.$228,336. Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the three months ended March 31, 2022,2023, the Company used $4,206$4,214 of cash in its operations. Cash on hand as of March 31, 20222023 was $36,176.$16,277.
As described in Note 8,10, Notes payable, net, borrowings under the Company’s secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of March 31, 2022,2023, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of March 31, 20222023 is approximately $34,176. With$14,277.
In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this unrestrictedmethodology, we evaluate whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable.
Our expectation to generate operating losses and negative operating cash balance,flows in the Company believes that it currently has sufficient cashfuture and the need for additional funding to fund itssupport our planned operations beyond the look forwardraise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management intends to raise funds through one or more financings. However, due to several factors, including those outside management’s control, there can be no assurance that the Company will be able to complete such financings on acceptable terms or in amounts sufficient to continue operating the business under the operating plan. If we are unable to complete sufficient additional financings, management’s plans include delaying or abandoning certain product development projects, cost reduction efforts for our products, and refocused sales efforts to accelerate revenue growth above historical results. We have concluded the likelihood that our plan to successfully reduce
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
expenses to align with our available cash is probable. Accordingly, we believe our plan will be sufficient to alleviate substantial doubt for a period of at least 12 months from the date of issuance of these condensed consolidated financial statements.statements which is in the second quarter of 2024.
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates
Basis of Presentation and Consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021,2022, which was filed with the SEC on February 24, 2022.March 28, 2023.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2021,2022, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.
Certain reclassifications have been made to the amounts in prior periods to conform to the current period’s presentation.
The results of operations for the three months ended March 31, 20222023 are not necessarily indicative of the results to be expected for the year ending December 31, 20222023 or any future periods.
The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, assets acquired and liabilities assumed in business combinations, revenue recognition, deferred revenue, and the deferral of the associated costs, the valuation of warrants and employee stock options,equity awards, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.
Foreign Currency
The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.
Inventory
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw materials. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.
Leases
The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.
Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.
Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.
Revenue Recognition
The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.
For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of the Company’s markets.customer. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.
The Company exercised judgement to determine that a product returnsreturn reserve was not required as historical returns activity have not been material.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Going Concern
The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
Concentration of Credit Risk and Other Risks and Uncertainties
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintainshas significant cash accounts in excess ofbalances at financial institutions which throughout the year regularly exceed the federally insured limits. However,limit of $250. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company believes it is not exposed to significant credit risk due to theCompany's financial positioncondition, results of the depository institutions in which these deposits are held.operations, and cash flows. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.
Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days. The Company has not experienced material losses related to accounts receivable as of March 31, 20222023 and December 31, 2021. 2022.
Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contractscollecting receivables denominated in a foreign currency.
At March 31, 2022,2023 the Company had 1 one customer (10%) with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable (30%) as compared with zerono customers at December 31, 2021.2022.
During the three months ended March 31, 2022,2023, the Company had 1 customer two customers with sales of 10% or more of the Company’s total revenue (11%(26% and 14%), as compared with 2 customersone in the three months ended March 31, 2021 (14% and 11%, respectively)2022 (11%).
Recent Accounting Pronouncements Adopted in 2023
In June 2016, the FASB issued Accounting StandardsStandard Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, and ASU 2022-02, which amendsamended the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will beis based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently,Previously, U.S. GAAP requiresrequired entities to write down credit losses only when losses arewere probable and loss reversals arewere not permitted. The update will be effective forCompany adopted ASU 2016-13 as of January 1, 2023, using the Company beginning in the first quarter of 2023. Early adoption is permitted.modified retrospective transition method. The Company is currently evaluating the impact the adoption of this standard willASU 2016-13 did not have a material impact on its condensed consolidatedthe Company's financial statements and related disclosures.position or the results of operations.
Recent Accounting Pronouncements
In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2024 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2020-06 to be material on its consolidated financial statements.
3. Accumulated Other Comprehensive Income (Loss)
The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the three months ended March 31, 20222023 and 2021,2022, is reflected in the table below net of tax:
| | | Three Months Ended March 31, | | Three Months Ended March 31, |
| | 2022 | 2021 | | 2023 | 2022 |
Balance at beginning of period | Balance at beginning of period | $ | (17) | | $ | (847) | | Balance at beginning of period | $ | 563 | | $ | (17) | |
Net unrealized gain on foreign currency translation | 212 | | 465 | | |
Net unrealized (loss) gain on foreign currency translation | | Net unrealized (loss) gain on foreign currency translation | (194) | | 212 | |
Balance at end of period | Balance at end of period | $ | 195 | | $ | (382) | | Balance at end of period | $ | 369 | | $ | 195 | |
4. Human Motion and Control Acquisition
On December 5, 2022, the Company acquired the HMC business from Parker. The assets acquired from the business unit include intellectual property rights for devices which are FDA-cleared lower-limb powered exoskeletons that enable task-specific, overground gait training to patients with weakness or paralysis in their lower extremities. Products include Ekso Indego Personal, a light-weight exoskeleton for safe use in most home and community environments, and Ekso Indego Therapy, an adjustable exoskeleton for patients with spinal cord injury and stroke, complementing Ekso’s product offering in outpatient facilities.
The assets purchased by the Company include intellectual property related to the aforementioned Ekso Indego devices and future products in the orthotics and prosthetics space, inventories related to the Ekso Indego product line, fixed assets configured for the manufacture of the Ekso Indego products, and Ekso Indego devices maintained for service and sales demonstrations. The Company did not acquire any cash in connection with the acquisition of the business unit.
As consideration for the assets acquired, the Company (i) paid the Parker $5,000 in cash and (ii) delivered to Parker a $5,000 unsecured, subordinated zero percent interest promissory note (the “Promissory Note”). Under the terms of the Promissory Note, the Company shall pay Parker sixteen (16) equal quarterly installments of $313, with the first payment being due and payable December 31, 2023, and the last payment being due and payable September 30, 2027. For additional information see Note 10.
The Company accounted for the acquisition as a business combination in accordance with ASC 805, Business Combinations, by applying the acquisition method, and accordingly, the purchase price of $9,055, as calculated in the table below, was allocated to the assets acquired and liabilities assumed based on their fair values at the acquisition date. The fair values presented for fixed assets, intangible assets, and goodwill are preliminary figures pending final fair value analyses. In accordance with ASC 805, the acquirer has a year from the date of acquisition to recognize measurement period adjustments. The preliminary fair values presented below could be subject to change as result of the aforementioned adjustments. The excess of the purchase price over the preliminary net assets acquired of $431 was recorded as goodwill. The goodwill recognized is attributed primarily to expected synergies of HMC with the Company. From the acquisition date and as of March 31, 2023, there were no changes in the recognized amounts of goodwill resulting from the acquisition.
The following table summarizes the preliminary fair values of the assets acquired, liabilities assumed and consideration given as of the acquisition date. These estimates are preliminary, pending final evaluation of certain assets, and therefore, are subject to revisions that may result in adjustments to the values presented below:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | |
Inventories | $ | 1,935 | |
Fixed assets | 1,599 | |
Intangible assets | 5,240 | |
Goodwill | 431 | |
Total assets | $ | 9,205 | |
| |
Accrued royalties | 150 | |
Total liabilities | $ | 150 | |
| |
Net assets acquired | $ | 9,055 | |
| |
Cash delivered at close | $ | 5,000 | |
Fair value of promissory note | 4,055 | |
Total consideration | $ | 9,055 | |
The fair value of finished goods inventories acquired was estimated at retail selling price less estimated costs to sell and a reasonable profit allowance for the selling effort. The fair value of raw materials acquired were estimated using current prices from suppliers. The fair value of fixed assets was estimated using a cost approach, adjusting historical gross asset values for inflation, reduced for the remaining estimated economic life of the assets. The preliminary fair values of intangible assets were estimated using a relief from royalty method, the excess earnings method, and a distributor method, all income approaches, which required significant estimates from management regarding future sales expectations, long term operating margins, the weighted average cost of capital or other appropriate discount rates, and royalty rates. The fair value of the promissory note was estimated as the present value of scheduled principal payments discounted at the Company's estimated borrowing rate.
The Company recorded $5,240 to intangible assets as of the acquisition date and is amortizing the value of the developed technology, customer relationships and intellectual property over a weighted average estimated useful life of eight years. Amortization expense related to the acquired definite lived intangible assets was $82 for the three months ended March 31, 2023, and was included as a component of operating expenses and cost of revenue in the consolidated statement of operations and comprehensive loss. Of the $431 of goodwill, none was expected to be deductible for tax purposes.
5. Fair Value Measurement
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:
•Level 1—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities;liabilities, quoted prices in markets that are not active;active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows:
| | | | Total | | Level 1 | | Level 2 | | Level 3 | | | Total | | Level 1 | | Level 2 | | Level 3 |
March 31, 2022 | | | | | | | | | |
March 31, 2023 | | March 31, 2023 | | | | | | | | |
Liabilities | Liabilities | | | | | | | | | Liabilities | | | | | | | | |
Warrant liabilities | Warrant liabilities | | $ | 1,650 | | | $ | — | | | $ | — | | | $ | 1,650 | | Warrant liabilities | | $ | 259 | | | $ | — | | | $ | — | | | $ | 259 | |
| December 31, 2021 | | |
| December 31, 2022 | | December 31, 2022 | |
Liabilities | Liabilities | | Liabilities | |
Warrant liabilities | Warrant liabilities | | $ | 1,550 | | | $ | — | | | $ | — | | | $ | 1,550 | | Warrant liabilities | | $ | 233 | | | $ | — | | | $ | — | | | $ | 233 | |
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the periodthree months ended March 31, 2022,2023, which were measured at fair value on a recurring basis:
| | | | | | | | |
| | Warrant Liability |
Balance at December 31, 20212022 | | $ | 1,550233 | |
| | |
Loss on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings | | 100 |
| | |
| | |
Net loss on revaluation of warrants issued | | 26 | |
Balance at March 31, 20222023 | | $ | 1,650259 | |
Refer to Note 10.12. Capitalization and Equity Structure – Warrants for additional information regarding the valuation of warrants.
5.6. Inventories
Inventories consisted of the following: | | | March 31, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
Raw materials | Raw materials | $ | 2,218 | | | $ | 2,061 | | Raw materials | $ | 3,907 | | | $ | 3,837 | |
Work in progress | Work in progress | 308 | | | 145 | | Work in progress | 705 | | | 487 | |
Finished goods | Finished goods | 246 | | | 36 | | Finished goods | 1,050 | | | 863 | |
| Inventories | Inventories | $ | 2,772 | | | $ | 2,242 | | Inventories | $ | 5,662 | | | $ | 5,187 | |
6.7. Revenue
The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, associated software (SmartAssistEksoUE, Ekso Indego Therapy, and VariableAssist), the sale and subscription of the EksoUE, the sale of accessories, andEkso Indego Personal devices, along with the sale of support and maintenance contracts (Ekso Care). In 2021, the Company moved to a customer subscription sales model and away from a rental sales model. Under the rental sales model, the Company offered customers a short-term rental arrangement of its products to help bridge to a capital purchase since customers typically have challenges in obtaining approvals for capital expenditures. Subscription sales arrangements, however, bypass the customer capital purchase process, are intended to renew annually, and provide a long-term revenue stream.
contracts. Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, softwareEkso UE, Ekso Indego Therapy, and accessories. Ekso Care supportIndego Personal devices. Support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements. The separately priced Ekso Caresupport and maintenance contracts range from 12 to 48 months. The Company typically receives payment at the inception of the contract and recognizes revenue evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the initial contract term, typically over 12 months.
The Company’s industrial device segment (EksoWorks) revenue is primarily generated through the sale and subscription of the upper body exoskeleton EVO and associated accessories. Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility. Revenue from industrial device subscriptions is recognized evenly over the contract term, typically 12 months.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
In June 2022, the Company ceased commercialization of the EksoZeroG support arm and related products and accessories. Refer to Note 15. Commitment and Contingencies for further information regarding commitments and obligations related to the EksoZeroG product line.
Deferred Revenue
Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts, but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.
Deferred revenue consisted of the following: | | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 |
Deferred extended maintenance and support | $ | 2,519 | | | $ | 2,124 | |
Customer advances | 144 | | | 29 | |
Total deferred revenues | 2,663 | | | 2,153 | |
Less current portion | (1,296) | | | (1,121) | |
Deferred revenues, non-current | $ | 1,367 | | | $ | 1,032 | |
Deferred revenue activity consisted of the following for the three months ended March 31, 2023: | | | | | |
| |
Beginning balance | $ | 2,153 | |
Deferral of revenue | 1,170 | |
Recognition of deferred revenue | (660) | |
Ending balance | $ | 2,663 | |
The Company expects to recognize approximately $1,080 of the deferred revenue during the remainder of 2023, $795 in 2024, and $788 thereafter.
In addition to deferred revenue, the Company has a non-cancellable backlog of $1,396, expected to be recognized between 2023 and 2025, related to its contracts for subscription units with its customers. These subscription contracts typically have 12 to 24 month terms, and subscription income is recognized on a straight-line basis over the term of the contract.
Disaggregation of Revenue
The following table disaggregates the Company’s revenue by major source for the three months ended March 31, 2023: | | | | | | | | | | | | | | | | | |
| EksoHealth | | EksoWorks | | Total |
Device revenue | $ | 3,048 | | | $ | 111 | | | $ | 3,159 | |
Service and support | 644 | | | — | | | 644 | |
Subscriptions | 275 | | | 7 | | | 282 | |
Parts and other | 30 | | | 7 | | | 37 | |
| | | | | |
| $ | 3,997 | | | $ | 125 | | | $ | 4,122 | |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The following table disaggregates the Company’s revenue by major source for the three months ended March 31, 2022: | | | | | | | | | | | | | | | | | |
| EksoHealth | | EksoWorks | | Total |
Device revenue | $ | 963 | | | $ | 309 | | | $ | 1,272 | |
Service and support | 467 | | | — | | | 467 | |
Subscriptions | 216 | | | 69 | | | 285 | |
Parts and other | 156 | | | 308 | | | 464 | |
Collaborative arrangements | 79 | | | — | | | 79 | |
| $ | 1,881 | | | $ | 686 | | | $ | 2,567 | |
8. Accrued Liabilities
Accrued liabilities consisted of the following: | | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 |
Salaries, benefits and related expenses | $ | 1,739 | | | $ | 1,843 | |
Device warranty | 301 | | | 274 | |
| | | |
| | | |
Other | 187 | | | 161 | |
Total | $ | 2,227 | | | $ | 2,278 | |
Warranty
The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three months ended March 31, 2023 is as follows:
| | | | | | | | | | | | |
| | | Three months ended | | | | | |
| | | March 31, 2023 | | | | | |
Balance at beginning of period | | | $ | 413 | | | | | | |
Additions for estimated future costs | | | 113 | | | | | | |
Incurred costs | | | (100) | | | | | | |
Balance at end of period | | | $ | 426 | | | | | | |
| | | | | | | | |
| | | Balance as of March 31, 2023 | | | | | |
Current portion | | | $ | 308 | | | | | | |
Long-term portion | | | 118 | | | | | | |
Total | | | $ | 426 | | | | | | |
9. Goodwill and Intangible Assets
Goodwill
The Company determined no impairment existed for goodwill for the three months ended March 31, 2023.
Intangible Assets
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The Company’s industrial device segment (EksoWorks) revenue is generated throughfollowing table summarizes the salecomponents of the upper body exoskeletons (EksoVestpreliminary gross assets, accumulated amortization, and the EVO)net carrying values for definite and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when controlindefinite lived intangible asset balances as of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility.
Contract Balances
Timing of revenue recognition may differ from the timing of invoicing to customers and receipt of payment. For the sale of its products, the Company generally recognizes revenue at a point in time through the ship-and-bill performance obligations. For the subscription of its products, the Company generally recognizes revenue over the subscription term commencing upon the completion of customer training. For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.March 31, 2023:
Deferred revenue | | | | | | | | | | | | | | | | | |
| March 31, 2023 |
| Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount |
Developed technology | $ | 2,310 | | | $ | (93) | | | $ | 2,217 | |
Trade name | 2,310 | | | N/A | | 2,310 | |
Intellectual property | 460 | | | — | | | 460 | |
Customer relationships | 140 | | | (6) | | | 134 | |
Below market lease | 20 | | | (5) | | | 15 | |
Total intangible assets | $ | 5,240 | | | $ | (104) | | | $ | 5,136 | |
Definite lived intangible assets are amortized over their estimated lives using the straight line method, which is comprised mainly of unearned revenue relatedestimated as 8 years for developed technology, 12 years for intellectual property, eight years for customer relationships and one year for below market lease. The acquired trade name was estimated to extended supporthave an indefinite life, and maintenance contracts (Ekso Care), but also includes other offeringsconsequently, no amortization expense was recorded. The Company determined no impairment existed for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.
Deferred revenue consisted of the following: | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Deferred extended maintenance and support | $ | 2,124 | | | $ | 2,349 | |
Deferred royalties | — | | | 280 | |
Deferred device and advances | 73 | | | 66 | |
Total deferred revenues | 2,197 | | | 2,695 | |
Less current portion | (1,115) | | | (1,220) | |
Deferred revenues, non-current | $ | 1,082 | | | $ | 1,475 | |
Deferred revenue activity consisted of the followingintangible assets for the three months ended March 31, 2022: | | | | | |
| |
Beginning balance | $ | 2,695 | |
Deferral of revenue | 196 | |
Recognition of deferred revenue | (694) | |
Ending balance | $ | 2,197 | |
As of March 31, 2022, the Company’s deferred revenue was $2,197. The Company expects to recognize approximately $902 of the deferred revenue during the remainder of 2022, $681 in 2023, and $614 thereafter.
In addition to deferred revenue, the Company has a non-cancellable backlog of $1,524 related to its contracts for subscription units with its customers. These subscription contracts typically have 12-month terms and subscription income is recognized on a straight-line basis over the lease term.
In the three months ended March 31, 2022 the Company recognized revenue of $280 related to a $300 upfront royalty payment associated with a license and distribution agreement that expired. The unrecognized royalty balance of $280 was included in deferred revenue as of December 31, 2021.
As of March 31, 2022 and December 31, 2021, total accounts receivable, net of allowance for doubtful accounts, were $3,486 and $4,824, respectively, and are included in accounts receivable, net and other assets on the Company’s condensed consolidated balance sheets.
The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.
Disaggregation of revenue
The following table disaggregates the Company’s revenue by major source for the three months ended March 31, 2022:
| | | | | | | | | | | | | | | | | |
| EksoHealth | | EksoWorks | | Total |
Device revenue | $ | 963 | | | $ | 309 | | | $ | 1,272 | |
Service and support | 467 | | | — | | | 467 | |
Subscriptions | 216 | | | 69 | | | 285 | |
Parts and other | 156 | | | 308 | | | 464 | |
Collaborative arrangements | 79 | | | — | | | 79 | |
| $ | 1,881 | | | $ | 686 | | | $ | 2,567 | |
2023.
The following table disaggregates the Company’s revenue by major source for the three months endedestimated future amortization expenses related to definite lived intangible assets as of March 31, 2021:2023 is as follows (in thousands):
| | | | | | | | | | | | | | | | | |
| EksoHealth | | EksoWorks | | Total |
Device revenue | $ | 1,019 | | | $ | 98 | | | $ | 1,117 | |
Service and support | 488 | | | — | | | 488 | |
Rentals and subscriptions | 152 | | | 70 | | | 222 | |
Parts and other | 54 | | | 15 | | | 69 | |
Collaborative arrangements | 14 | | | — | | | 14 | |
| $ | 1,727 | | | $ | 183 | | | $ | 1,910 | |
| | | | | |
Fiscal Year | Amount |
2023 - remainder | $ | 320 | |
2024 | 306 | |
2025 | 345 | |
2026 | 345 | |
2027 | 345 | |
2028 and thereafter | 1,164 | |
Total | $ | 2,825 | |
7. Accrued Liabilities
Accrued liabilities consisted of the following: | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Salaries, benefits and related expenses | $ | 1,520 | | | $ | 2,015 | |
Device warranty | 226 | | | 195 | |
| | | |
| | | |
Other | 73 | | | 89 | |
Total | $ | 1,819 | | | $ | 2,299 | |
The current portion of the device warranty liability is classified as a component of accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three months ended March 31, 2022 is as follows:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | |
| Three Months Ended | | | | | | |
| March 31, 2022 | | |
Balance at beginning of period | $ | 270 | | | | | | | |
Additions for estimated future costs | 76 | | | | | | | |
Incurred costs | (60) | | | | | | | |
Balance at end of period | $ | 286 | | | | | | | |
| | | | | | | |
| Balance as of March 31, 2022 |
Current portion | $ | 226 | |
Long-term portion | 60 | |
Total | $ | 286 | |
8.10. Notes Payable, net
PWB Term Loan
In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its “prime rate” then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.
The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. Upon maturity, all unpaid principal and accrued and unpaid interest shall be due and payable in full. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.
The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of March 31, 2022.2023. On March 31, 2022,2023, with cash on hand of $36,176,$16,277, the Company was compliant with this liquiditycovenant. In March 2023, the Company entered into an amendment to the PWB Loan Agreement increasing
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
the primary depository covenant and all other covenants.which restricts the Company from having more than $3,000 held in subsidiary accounts outside of the United States until July 2, 2023 at which time the amount decreases to $1,000.
The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 4.70%8.54% for the three months ended March 31, 2022.2023. The debt issuance costs will beare amortized to interest expense using the effective interest method over the life of the loan.
The following table presents scheduled principal payments of the Company’s PWB term loan as of March 31, 2022:2023:
| | | | | | | | |
Period | | Amount |
2023 - remainder | | $ | 2,000 | |
| | |
Total principal payments | | 2,000 | |
Less debt discount and issuance cost | | 2 | |
Note payable, net | | $ | 1,998 | |
| | |
Current portion | | $ | 1,998 | |
Long-term portion | | — | |
Note payable, net | | $ | 1,998 | |
Parker Hannifin Promissory Note
In connection with the HMC Acquisition, on December 5, 2022, the Company delivered a $5,000 unsecured, subordinated promissory note (the "Promissory Note") to Parker. The Promissory Note, subordinate to the PWB Term Loan, bears no interest with principal payable in sixteen equal installments due on the last day of each quarter, commencing on December 31, 2023 and maturing on September 30, 2027. For additional information see Note 4.
The Promissory Note, upon the occurrence of an event of default, allows for the levying of interest equal to the lesser of (a) 5% per annum and (b) the maximum interest rate permitted under applicable law on the then entire outstanding principal balance, and also for the acceleration of all outstanding liabilities and obligations, making them immediately payable. Under the terms of the Promissory Note, the following occurrences constitute a default, and could, upon written notice or declaration by Parker Hannifin Corporation, allow for the levying of interest and or the acceleration of principal outstanding: (i) failure to pay any amount of the principal when due and payable, (ii) the dissolution of the Company (including the declaration of bankruptcy), and (iii) the acquisition of the Company by another entity or the sale of substantially all of its assets to another entity.
The Company recorded the Promissory Note of $4,055 in its condensed consolidated balance sheets under the captions Notes Payable, Current and Notes Payable, Net, estimating an implicit discount rate of 7.5% via reference to the interest charged on the Company's PWB Term Loan and other relevant economic factors present at the execution date of the Promissory Note. The amortization of debt discounts resulted in an effective interest rate of 7.6% for the three months ended March 31, 2023. The debt discount is amortized to interest expense using the effective interest method over the life of the loan. Interest expense on the Promissory Note was $79 for the three months ended March 31, 2023.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | |
Period | | Amount |
Remainder of 2022 | | $ | — | |
2023 | | 2,000 | |
Total principal payments | | 2,000 | |
Less debt discount and issuance cost | | 6 | |
Note payable, net | | $ | 1,994 | |
| | |
Current portion | | $ | — | |
Long-term portion | | 1,994 | |
Note payable, net | | $ | 1,994 | |
Paycheck Protection Program Loan
On April 20, 2020, the Company received an unsecured loan in theThe following table presents scheduled principal amount of $1,086 under the Paycheck Protection Program (the “PPP”) administered by the U.S. Small Business Administration (the "SBA"), pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), or the PPP loan. The PPP loan bore interest at 1.00% per annum, and matured two years after the date of initial disbursement. The termspayments of the PPP loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on June 5, 2020. The PPP loan was used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments and interest payments on other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company could apply for and be granted forgiveness for all or a portion of loan granted under the PPP loan, with such forgiveness to be determined, subject to limitations (including where employees of the Company have been terminated and not re-hired by a certain date), based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness were also subject to further requirements in regulations and guidelines adopted by the SBA.
On June 28, 2021, the Company received notification from the SBA that the Company’s Forgiveness Application of the PPP loan and accrued interest, totaling $1,099, was approved in full, and the Company had no further obligations related to the PPP loan. Accordingly, the Company recorded a gain on the forgiveness of the PPP loan as gain on forgiveness ofCompany's note payable on the condensed consolidated statementas of operations during the three months ended June 30, 2021.March 31, 2023:
| | | | | |
Period | Amount |
2023 - remainder | $ | 313 | |
2024 | 1,250 | |
2025 | 1,250 | |
2026 | 1,250 | |
2027 | 937 | |
Total principal payments | 5,000 | |
Less debt discount | (841) | |
Note payable, net | $ | 4,159 | |
| |
Current portion | 625 | |
Long-term portion | 3,534 | |
Note payable, net | $ | 4,159 | |
9.11. Lease Obligations
The Company maintainsmaintained a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California (the "Richmond Lease") which expires inexpired at the end of May 2022, with no further options2022. The Company continued to extend or terminate. Themaintain its tenancy at this location until the end of August 2022. Pursuant to the terms of the original lease includes non-lease components (i.e.agreement, the Company incurred monthly expenses equal to the most recent monthly lease payment under the now expired lease agreement and common area maintenance costs) that are paid separately from rent based on actual costs incurred.plus a 25% mark-up.
In July 2022, the Company entered into an operating lease agreement for its new headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") expiring in October 2026 with the option to renew for an additional three-year period at the prevailing market rate at the time of extension. At the end of August 2022, the Company relocated to its new headquarters and manufacturing facility in San Rafael.
The Company maintainshas determined that the new San Rafael Lease constitutes an operating lease under ASC 842 and estimates the lease term as July 2022 through October 2026. The option to extend for a three-year period lacks significant economic incentives and disincentives, which would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term have been discounted at the Company's estimated incremental borrowing rate as of the date of contract execution and are reflected in the condensed consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for the San Rafael Lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.
The Company previously maintained a five-year operating lease agreement for its European operations office in Hamburg, Germany, which expireswas originally set to expire in July 2022. In February 2022, the Company executed a new lease agreement with the same landlord for a replacement office in Hamburg, Germany commencing May 1, 2022 and expiring June 30, 2025 with an option to renew for 1one five-year period. Since this operatingUpon the early termination of the previous lease commences after March 31, 2022,agreement, it was agreed between the landlord and the Company that access to the previously leased office space would be revoked and the Company would be relieved of its payment obligations for the final two months of the lease payments are not recognizedterm. Consequently, the Company removed the right of use asset and lease liability, $15 and $16 respectively, recorded in lease liabilities and corresponding right-of-use assets onits condensed consolidated financial statements related to the balance sheet as of March 31, 2022.original Hamburg tenancy.
The Company’s futureCompany has determined that the new Hamburg lease agreement constitutes a lease under ASC 842 and estimates the lease term as May 2022 through June 2025. The option to extend for a five-year period lacks significant economic incentives and disincentives which would make exercise reasonably certain. Fixed lease payments as of March 31, 2022, whichfor identified lease components over the identified term have been discounted at the Company's estimated incremental borrowing rate and are presented as lease liabilities onreflected in the Company’s condensed consolidated balance sheets are as follows:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | |
Period | | Operating Leases |
Remainder of 2022 | | $ | 98 | |
2023 | | — | |
Total lease payments | | 98 | |
Less: imputed interest | | (1) | |
Present value of lease liabilities | | $ | 97 | |
| | |
Weighted-average remaining lease term (in years) | | 0.2 |
Weighted-average discount rate | | 10.5 | % |
consolidated balance sheets under the captions Lease liabilities, current and Lease liabilities, and the corresponding right of use asset is reflected in the condensed consolidated balance sheets under the caption Right-of-use assets. Non-lease components, such as common area maintenance costs, are excluded from the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term.The Company’s future lease payments as of March 31, 2023, which are presented as Lease liabilities, current and Lease liabilities on the Company’s condensed consolidated balance sheets are as follows:
| | | | | | | | |
Periods | | Operating Leases |
2023 - remainder | | $ | 308 | |
2024 | | 421 | |
2025 | | 402 | |
2026 | | 349 | |
2027 | | — | |
Total lease payments | | 1,480 | |
Less: imputed interest | | (132) | |
Present value of lease liabilities | | $ | 1,348 | |
| | |
Weighted-average remaining lease term (in years) | | 3.45 |
Weighted-average discount rate | | 5.4 | % |
Lease expense under the Company’s operating leases was $142$133 and $132$142 for the three months ended March 31, 20222023 and 2021,2022, respectively.
10.12. Capitalization and Equity Structure
Summary
The Company’s authorized capital stock at March 31, 20222023 and December 31, 20212022 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. As of March 31, 20222023 and December 31, 2021,2022, there were 12,84413,342 and 12,693,13,203, respectively, shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.
Common Stock
February 2021 Offering
In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for a public price of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering"). The Company received net proceeds of $36,504 from the February 2021 Offering after deducting underwriting discounts, commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued, to certain designees of Wainwright, five year warrants (the “2021 Warrants”) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering, or 273 shares, at an exercise price of $12.81 per share.
At the Market Offering
In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. The Company may offer and sell shares having an aggregate offering price of up to $7,500 under the registration statement and prospectus supplement filed with the SEC related to such offering. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share. The Company did not sell any shares under the ATM agreement during the three months ended March 31, 2023 and 2022. As of March 31, 2022,2023, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Warrants
Warrants outstanding as of March 31, 20222023 and December 31, 20212022 were as follows:
| Source | Source | | Exercise Price | | Term (Years) | | December 31, 2021 | | Issued | | Exercised | | March 31, 2022 | Source | | Exercise Price | | Term (Years) | | December 31, 2022 | | Issued | | Exercised | | March 31, 2023 |
2021 Warrants | 2021 Warrants | | $ | 12.81 | | | 5 | | 273 | | | — | | | — | | | 273 | | 2021 Warrants | | $ | 12.81 | | | 5 | | 273 | | | — | | | — | | | 273 | |
June 2020 Investor Warrants | June 2020 Investor Warrants | | $ | 5.18 | | | 5.5 | | 127 | | | — | | | — | | | 127 | | June 2020 Investor Warrants | | $ | 5.18 | | | 5.5 | | 127 | | | — | | | — | | | 127 | |
June 2020 Placement Agent Warrants | June 2020 Placement Agent Warrants | | $ | 5.64 | | | 5 | | 39 | | | — | | | — | | | 39 | | June 2020 Placement Agent Warrants | | $ | 5.64 | | | 5 | | 39 | | | — | | | — | | | 39 | |
December 2019 Warrants | December 2019 Warrants | | $ | 8.10 | | | 5 | | 556 | | | — | | | — | | | 556 | | December 2019 Warrants | | $ | 8.10 | | | 5 | | 556 | | | — | | | — | | | 556 | |
December 2019 Placement Agent Warrants | December 2019 Placement Agent Warrants | | $ | 8.44 | | | 5 | | 52 | | | — | | | — | | | 52 | | December 2019 Placement Agent Warrants | | $ | 8.44 | | | 5 | | 52 | | | — | | | — | | | 52 | |
May 2019 Warrants | May 2019 Warrants | | $ | 3.52 | | | 5 | | 193 | | | — | | | — | | | 193 | | May 2019 Warrants | | $ | 3.52 | | | 5 | | 193 | | | — | | | — | | | 193 | |
| | | 1,240 | | | — | | | — | | | 1,240 | | | | 1,240 | | | — | | | — | | | 1,240 | |
During the three months ended March 31, 2021, the Company received net proceeds of $1,417 from the exercise of 358 warrants and issued 300 shares of common stock, respectively, as a result of those exercises. No warrants were exercised during the three months ended March 31, 2023 and 2022.
2021 Warrants
In February 2021, the Company issued the 2021 Warrants,warrants (the "2021 Warrants"), exercisable for up to 273 shares of the Company’s common stock at an exercise price of $12.81 per share. The 2021 Warrants were exercisable immediately, and will expire five years from the date of issuance, or on February 11, 2026.
In addition, the 2021 Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its 2021 Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the 2021 Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the 2021 Warrants. The 2021 Warrants will be automatically exercised on a cashless basis on their expiration date. The 2021 Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants.
The 2021 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the 2021 Warrants, the Company or any successor entity will, at the option of a holder of a 2021 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s 2021 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s 2021 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the 2021 Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the 2021 Warrants is measured at fair value upon issuance and at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the 2021 Warrants:
| | | March 31, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
Current share price | Current share price | $ | 2.89 | | | $ | 2.65 | | Current share price | $ | 1.65 | | | $ | 1.19 | |
Conversion price | Conversion price | $ | 12.81 | | | $ | 12.81 | | Conversion price | $ | 12.81 | | | $ | 12.81 | |
Risk-free interest rate | Risk-free interest rate | 2.44 | % | | 1.13 | % | Risk-free interest rate | 4.68 | % | | 4.21 | % |
Expected term (years) | Expected term (years) | 3.86 | | 4.11 | Expected term (years) | 2.86 | | 3.11 |
Volatility of stock | Volatility of stock | 95.67 | % | | 98.3 | % | Volatility of stock | 93.5 | % | | 99.6 | % |
June 2020 Investor Warrants
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
June 2020 Investor Warrants
In June 2020, the Company issued warrants (the "June 2020 Investor Warrants"), exercisable for up to 874 shares of the Company’s common stock at an exercise price of $5.18 per share. The June 2020 Investor Warrants were immediately exercisable, and will expire five and one-half years from the date of issuance, or on December 10, 2025.
In addition, the June 2020 Investor Warrants contain a cashless exercise provision, whereby, if, at the time a holder exercises its June 2020 Investor Warrants, a registration statement registering the issuance or the resale of the shares of common stock underlying the June 2020 Investor Warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect to instead receive, upon such exercise (either in whole or in part), the net number of shares of the Company’s common stock determined according to a formula set forth in the June 2020 Investor Warrant. The June 2020 Investor Warrants will be automatically exercised on a cashless basis on their expiration date.
The June 2020 Investor Warrants could also require payment of liquidated damages by the Company in the form of cash payments in the event of a failure by the Company to timely deliver shares of common stock upon exercise of such warrants. During the three months ended March 31, 2022 and 2021, no shares and 270 shares of the June 2020 Investor Warrants were exercised, respectively.
The June 2020 Investor Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the June 2020 Investor Warrants, the holders of the June 2020 Investor Warrants will be entitled to receive upon exercise of the June 2020 Investor Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the June 2020 Investor Warrants immediately prior to such fundamental transaction.Fundamental Transaction. Alternatively, the Company or any successor entity will, at the option of a holder of a June 2020 Investor Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s June 2020 Investor Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s June 2020 Investor Warrant. Because of this put-option provision, the June 2020 Investor Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the June 2020 Investor Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Investor Warrants:
| | | March 31, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
Current share price | Current share price | $ | 2.89 | | | $ | 2.65 | | Current share price | $ | 1.65 | | | $ | 1.19 | |
Conversion price | Conversion price | $ | 5.18 | | | $ | 5.18 | | Conversion price | $ | 5.18 | | | $ | 5.18 | |
Risk-free interest rate | Risk-free interest rate | 2.44 | % | | 1.11 | % | Risk-free interest rate | 4.73 | % | | 4.23 | % |
Expected term (years) | Expected term (years) | 3.69 | | 3.94 | Expected term (years) | 2.69 | | 2.94 |
Volatility of stock | Volatility of stock | 97.1 | % | | 103.9 | % | Volatility of stock | 72.5 | % | | 99.6 | % |
June 2020 Placement Agent Warrants
In June 2020, the Company issued warrants (the "June 2020 Placement Agent Warrants"), exercisable for up to 122 shares of the Company’s common stock, to the placement agent for such offering. The June 2020 Placement Agent Warrants have substantially the same form as the June 2020 Investor Warrants, including the put option described above, except that they have an exercise price per share equal to $5.64, subject to adjustment in certain circumstances, and will expire on June 7, 2025. During the three months ended March 31, 2022 and 2021, no shares and 83 shares of the June 2020 Placement Agent Warrants were exercised, respectively.
Because of the put-option provision in the June 2020 Placement Agent Warrants, these warrants are classified as a liability and are marked to market at each reporting date.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The warrant liability related to the June 2020 Placement Agent Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the June 2020 Placement Agent Warrants:
| | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 |
Current share price | $ | 2.89 | | | $ | 2.65 | |
Conversion price | $ | 5.64 | | | $ | 5.64 | |
Risk-free interest rate | 2.45 | % | | 1.03 | % |
Expected term (years) | 3.19 | | 3.44 |
Volatility of stock | 99.8 | % | | 100.0 | % |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 |
Current share price | $ | 1.65 | | | $ | 1.19 | |
Conversion price | $ | 5.64 | | | $ | 5.64 | |
Risk-free interest rate | 4.88 | % | | 4.33 | % |
Expected term (years) | 2.19 | | 2.44 |
Volatility of stock | 70.7 | % | | 73.5 | % |
December 2019 Warrants
In December 2019, pursuant to a securities purchase agreement (the "December 2019 Offering"), the Company issued warrants (the "December 2019 Warrants") to purchase 556 shares of common stock. The December 2019 Warrants are currently exercisable, have an exercise price of $8.10 per share, and will expire five years from the date they initially became exercisable, or on June 21, 2025.
The December 2019 Warrants also contain a cashless exercise provision and could require cash payments in the event of a failure to timely deliver securities or in the event of insufficient authorized shares. The December 2019 Warrants will be automatically exercised on a cashless basis on their expiration date. The December 2019 Warrants also contain a put option, under which, if the Company enters into a Fundamental Transaction, as defined in the December 2019 Warrants, the Company or any successor entity will, at the option of a holder of a December 2019 Warrant, exercisable concurrently with or at any time within 30 days after the consummation of such Fundamental Transaction, purchase such holder’s December 2019 Warrant by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such holder’s December 2019 Warrant within five trading days after the notice of exercise by the holder of the put option. Because of this put-option provision, the December 2019 Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the December 2019 Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Warrants:
| | | March 31, 2022 | | December 31, 2021 | | | March 31, 2023 | | December 31, 2022 | |
Current share price | Current share price | $ | 2.89 | | | $ | 2.65 | | | Current share price | $ | 1.65 | | | $ | 1.19 | | |
Conversion price | Conversion price | $ | 8.10 | | | $ | 8.10 | | | Conversion price | $ | 8.10 | | | $ | 8.10 | | |
Risk-free interest rate | Risk-free interest rate | 2.45 | % | | 1.04 | % | | Risk-free interest rate | 4.87 | % | | 4.32 | % | |
Expected term (years) | Expected term (years) | 3.22 | | 3.47 | | Expected term (years) | 2.22 | | 2.47 | |
Volatility of stock | Volatility of stock | 99.5 | % | | 99.7 | % | | Volatility of stock | 70.8 | % | | 73.3 | % | |
December 2019 Placement Agent Warrants
In December 2019, in connection with the December 2019 Offering, the Company issued warrants to purchase 52 shares of the Company’s common stock to the placement agent for such offering (the "December 2019 Placement Agent Warrants"). The December 2019 Placement Agent Warrants have substantially the same form as the December 2019 Warrants, except that they have an exercise price per share equal to $8.44, subject to adjustment in certain circumstances, and will expire on December 18, 2025.
The warrant liability related to the December 2019 Placement Agent Warrants is measured at fair value at each reporting date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were used in the Black-Scholes Model to measure the fair value of the December 2019 Placement Agent Warrants:
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | March 31, 2022 | | December 31, 2021 | | March 31, 2023 | | December 31, 2022 |
Current share price | Current share price | $ | 2.89 | | | $ | 2.65 | | Current share price | $ | 1.65 | | | $ | 1.19 | |
Conversion price | Conversion price | $ | 8.44 | | | $ | 8.44 | | Conversion price | $ | 8.44 | | | $ | 8.44 | |
Risk-free interest rate | Risk-free interest rate | 2.4 | % | | 0.96 | % | Risk-free interest rate | 4.95 | % | | 4.42 | % |
Expected term (years) | Expected term (years) | 2.72 | | 2.97 | Expected term (years) | 1.72 | | 1.97 |
Volatility of stock | Volatility of stock | 103.5 | % | | 102.9 | % | Volatility of stock | 62.1 | % | | 71.8 | % |
Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 Placement Agent Warrants), occurring during the term of the December 2019 Placement Agent Warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the warrants fair value is nominal.
May 2019 Warrants
In May 2019, pursuant to an underwriting agreement, (the "May 2019 Offering"), the Company issued the warrants (the "May 2019 Warrants") to purchase 444 shares of common stock. The May 2019 Warrants are currently exercisable, have a current exercise price of $3.52 per share, and will expire five years from the date of their issuance, or on May 24, 2024. The May 2019 Warrants contain a price protection feature, pursuant to which, subject to certain exceptions, if shares of common stock are sold or issued in the future, or securities convertible or exercisable for shares of the Company’s common stock are sold or issued in the future, for consideration, or with an exercise price or conversion price, as applicable, per share less than the exercise price per share then in effect for the May 2019 Warrants, the exercise price of the May 2019 Warrants is reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, the securities issued in such offering. Pursuant to this provision, in connection with the June 2020 Offering, the exercise price of the May 2019 Warrants was reduced to $3.52 per share, being the amount that is equal to the lower of (x) the consideration paid for the securities issued in the June 2020 Offering, or $4.51 per share, (y) the lowest exercise price of the June 2020 Investor Warrants, or $5.18, and (z) the lowest one-day volume-weighted average price of the Company’s Common Stock on the Nasdaq Capital Market as measured each day during the five trading day period starting on June 8, 2020, rounded to the nearest share, or $3.52. During the three months ended March 31, 2022 and 2021, 0 shares and 5 shares of the May 2019 warrants were exercised respectively.
In addition, if the Company effects or enters into any issuance of common stock or options or convertible securities exercisable for or convertible into common stock at a price which varies or may vary with the market price of the shares of the Company's common stock, subject to certain exceptions, a May 2019 Warrant holder may, at the time of exercise of the holder’s warrant, elect to exercise the warrant at such variable price.
The May 2019 Warrants include a put option, whereby while the May 2019 Warrants are outstanding, if the Company enters into a Change of Control, as defined in the May 2019 Warrants, the Company or any successor entity will, at the option of a 2019 Warrant holder exercise within 90 days after the public disclosure of the Change of Control transaction, purchase such holder’s May 2019 Warrants by paying to such holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of such warrants on the later date of consummation of the Change of Control transaction or two trading days after the notice of such request. Because of this put option provision, the May 2019 Warrants are classified as a liability and are marked to market at each reporting date.
The warrant liability related to the May 2019 Warrants is measured at fair value at each reporting and exercise date using certain estimated inputs, which are classified within Level 3 of the fair value hierarchy. The following assumptions were usedBecause of the price protection feature contained in the May 2019 Warrants, the Company uses a combination of the Black-Scholes Model and the Lattice Model to estimate the fair value of the warrants at each reporting period. The following assumptions were used in the Black-Scholes Model in combination with the Lattice Model to measure the fair value of the May 2019 Warrants:
| | | | | | | | | | | | |
| March 31, 2022 | | December 31, 2021 | |
Current share price | $ | 2.89 | | | $ | 2.65 | | |
Conversion price | $ | 3.52 | | | $ | 3.52 | | |
Risk-free interest rate | 2.31 | % | | 0.83 | % | |
Expected term (years) | 2.2 | | 2.4 | |
Volatility of stock | 108.6 | % | | 109.1 | % | |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | | |
| March 31, 2023 | | December 31, 2022 | |
Share price | $ | 1.65 | | | $ | 1.19 | | |
Conversion price | $ | 3.52 | | | $ | 3.52 | | |
Risk-free interest rate | 4.55 | % | | 4.6 | % | |
Expected term (years) | 1.2 | | 1.4 | |
Volatility of stock | 62.8 | % | | 74.5 | % | |
Management has assessed that the likelihood of a Change of Control occurring during the term of the warrants is low, and that if such an event were to occur, the difference between the cashless exercise value and the May 2019 Warrants fair value is nominal.
11.13. Stock-based Compensation
Shares available to grant
As of March 31, 2022,2023, the total number of shares authorized for grant under the Company's Amended and Restated 2014 Equity Incentive Plan was 1,974,2,524, of which 57653 were available for future grants.
Stock Options
The following table summarizes information about the Company’s stock options outstanding as of March 31, 2022,2023, and activity during the three months then ended:
| | | | | | | | | | | | | | | | | | | | | | | |
| Stock Awards | | Weighted- Average Exercise Price | | Weighted- Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value |
Balance as of December 31, 2021 | 491 | | | $ | 32.53 | | | | | |
| | | | | | | |
| | | | | | | |
Options forfeited | (26) | | | 10.58 | | | | | |
Options cancelled | (16) | | | 85.78 | | | | | |
Balance as of March 31, 2022 | 449 | | | $ | 31.96 | | | 5.12 | | $ | — | |
Vested and expected to vest at March 31, 2022 | 449 | | | $ | 31.96 | | | 5.12 | | $ | — | |
Exercisable as of March 31, 2022 | 402 | | | $ | 33.95 | | | 4.85 | | $ | — | |
| | | | | | | | | | | | | | | | | | | | | | | |
| Stock Awards | | Weighted- Average Exercise Price | | Weighted- Average Remaining Contractual Life (Years) | | Aggregate Intrinsic Value |
Balance as of December 31, 2022 | 270 | | | $ | 37.96 | | | | | |
| | | | | | | |
| | | | | | | |
Options forfeited | — | | | — | | | | | |
Options cancelled | (2) | | | 56.70 | | | | | |
Balance as of March 31, 2023 | 268 | | | $ | 37.85 | | | 5.00 | | $ | — | |
Vested and expected to vest at March 31, 2023 | 268 | | | $ | 37.85 | | | 5.00 | | $ | — | |
Exercisable as of March 31, 2023 | 262 | | | $ | 38.51 | | | 4.97 | | $ | — | |
As of March 31, 2022,2023, total unrecognized compensation cost related to unvested stock options was $526.$36. This amount is expected to be recognized as stock-based compensation expense in the Company’s condensed consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 1.080.63 years.
There were no stock options awarded during the three months ended March 31, 2023 and 2022.
Restricted Stock Units
The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employee service providers.members of the Board. Each RSU and PSU represents the right to receive 1one share of the Company’s common stock upon vesting and subsequent settlement. PSUs vest upon achievement of performance targets based on the Company's annual operating plan.
The fair values of RSUs and PSUs are determined based on the closing price of the Company’s common stock on the date of grant.
Combined RSU and PSU activity for the three months ended March 31, 20222023 is summarized below:
| | | | | | | | | | | |
| Number of Shares | | Weighted- Average Grant Date Fair Value |
Unvested as of December 31, 2021 | 655 | | | $ | 5.63 | |
Granted | 195 | | | 2.59 | |
Vested | (127) | | | 5.59 | |
Forfeited | (142) | | | 5.39 | |
Unvested at March 31, 2022 | 581 | | | $ | 4.69 | |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | |
| Number of Shares | | Weighted- Average Grant Date Fair Value |
Unvested as of December 31, 2022 | 1,383 | | | $ | 2.17 | |
Granted | — | | | — | |
Vested | (354) | | | 1.52 | |
Forfeited | — | | | — | |
Unvested at March 31, 2023 | 1,029 | | | $ | 2.40 | |
As of March 31, 2022, $1,9902023, $1,542 of total unrecognized compensation expense related to unvested RSUs and PSUs was expected to be recognized over a weighted average period of 1.721.46 years.
Compensation Expense
Total stock-based compensation expense related to options, RSUs and PSUs granted to employees and non-employee members of the board of directors is included in the condensed consolidated statements of operations and comprehensive loss as follows:
| | | | Three Months Ended March 31, | | Three Months Ended March 31, | |
| | | 2022 | | 2021 | | 2023 | | 2022 | |
Sales and marketing | Sales and marketing | | $ | 69 | | | $ | 99 | | Sales and marketing | $ | 64 | | | $ | 69 | | |
Research and development | Research and development | | 79 | | | 52 | | Research and development | 82 | | | 79 | | |
General and administrative | General and administrative | | 351 | | | 205 | | General and administrative | 278 | | | 351 | | |
| | | $ | 499 | | | $ | 356 | | | $ | 424 | | | $ | 499 | | |
401(k) Plan Share Match
During the three months ended March 31, 20222023 and 2021,2022, the Company issued 680 and 2668 shares of common stock with a fair value of $176$0 and $152,$176, to eligible employees’ deferral accounts for the 401(k) Plan matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the fiscal years ended December 31, 2022 and 2021, and 2020, respectively. The share issuance related to the matching of contributions for the year ended December 31, 2022 was delayed to the three months ended June 30, 2023.
The expense related to the accrual for the 401(k) plan share matching was $64$93 and $52$64 for the three months ended March 31, 20222023 and 2021,2022, respectively.
12.14. Income Taxes
There were no material changes to the unrecognized tax benefits in the three months ended March 31, 2022,2023, and the Company does not expect significant changes to unrecognized tax benefits through the end of the fiscal year. Because of the Company’s history of tax losses, all years remain open to tax examination.
13.15. Commitments and Contingencies
Material Contracts
The Company enters various license, research collaboration and development agreements, which provide for payments to the Company primarily for technology transfer and license fees, and royalty payments on sales.
The Company has 2two license agreements with the Regents of the University of California to maintain exclusive rights to certain patents. The Company is required to pay 1% of net sales of licensed medical devices sold to entities other than the U.S. government. In addition, the Company is required to pay 21% of consideration collected from any sub-licensee for the grant of the sub-license.
Under a license agreement with the developer
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The Company entered into a research and development collaboration agreement in December 2021 with a party that develops technologies having utility in robotic exoskeletons from research and development activities associated with a specific set of government funded research projects. Since January 2022, the Company has assisted with research and development activities in exchange for access to a worldwide, royalty free, transferable, sublicensable, exclusive license to design and market products that use or incorporate the jointly-developed technology within Ekso’s target market segments.
Ekso Bionics Holdings, Inc.
NotesIn connection with the HMC Acquisition, the Company assumed two license agreements with Vanderbilt University to Condensed Consolidated Financial Statements
($maintain exclusive rights to patents on the Company's behalf. The Vanderbilt Exoskeleton License Agreement was entered into as of October 15, 2012 and share amountswill continue until April 29, 2038, unless sooner terminated. Under this agreement, the Company is required to pay 6% of net sales of licensed patent products and 3% of net sales of licensed software products. The minimum annual royalty for licensed products is $250 after July 31, 2018. The Vanderbilt Knee License Agreement was entered into as of March 1, 2022 and will continue until February 15, 2041, unless sooner terminated. Under this agreement, the Company is required to pay the remaining issue fee balance of $100 on April 30, 2023, and pay 3.75% of net sales for licensed patent products and the minimum annual royalty is $75 due on or before July 31, 2028. In addition to the assumption of the license agreements, the Company entered into transitional use agreements with Parker granting the Company access to certain information technology systems and manufacturing facilities in thousands, except per share amounts)
(Unaudited)
Macedonia, Ohio for twelve months following the date of the acquisition. As consideration for access to these resources, the Company is required to make monthly payments of $20.
Purchase Obligations
The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $3,460 as of March 31, 2022, which are expected to be paid within two years, and $1,446 as of December 31, 2021. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.
Due to a variety of factors, including the COVID-19 pandemic, various materials the Company used to manufacture its products areis currently experiencing shortages and supply chain disruptions. Electronic components in general, semiconductor chips, battery cells, metals and plastics, all of which are used in the Company's products, are also in shorter supply compared to prior periods, and the Company is also experiencing longer lead times for manufacturing services such as machining and tool making. Numerous factors, such as the ongoing pandemic or further trade tensions between the U.S.making and China, may prolong or deepen these challenges.increased pricing.
In addition,The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $3,800 as of March 31, 2023, which are expected to be paid within one year, and $3,480 as of December 31, 2022. Timing of payments and actual amounts paid may be different depending on the time of receipt of goods or services or changes to agreed-upon amounts for some obligations.
The Company has operating lease commitments totaling $227 $1,480 payable ratably over three years43 months related to an operating lease which was executedthe San Rafael and Hamburg leases disclosed in February 2022 but does not commence until May 1, 2022. See Note 9.11. Lease Obligations.
Contingencies
In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not have a material adverse effect on the Company’s condensed consolidated financial statements.
14.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
16. Net (Loss) IncomeLoss Per Share
The following table sets forth the computation of basic and diluted net loss per share:
| | | | | | | | | | | | | | | |
| | | Three Months Ended March 31, |
| | | | | 2022 | | 2021 |
Numerator: | | | | | | | |
Net loss applicable to common stockholders, basic and diluted | | | | | $ | (4,620) | | | $ | (3,670) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Denominator: | | | | | | | |
| | | | | | | |
| | | | | | | |
Weighted-average number of shares, basic and diluted | | | | | 12,728 | | | 10,752 | |
| | | | | | | |
Net loss per share, basic and diluted | | | | | $ | (0.36) | | | $ | (0.34) | |
| | | | | | | |
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2023 | | 2022 | | | | |
Numerator: | | | | | | | |
Net loss applicable to common stockholders, basic and diluted | $ | (4,389) | | | $ | (4,620) | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Denominator: | | | | | | | |
Weighted-average number of shares, basic and diluted | 13,296 | | | 12,728 | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net loss per share, basic and diluted | $ | (0.33) | | | $ | (0.36) | | | | | |
| | | | | | | |
The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented: | | | | | | | | | | | | | | | | | | | |
| | | Three Months Ended March 31, | | |
| | | | | 2022 | | 2021 | | | | |
Options to purchase common stock | | | | | 449 | | | 522 | | | | | |
Restricted stock units | | | | | 581 | | | 325 | | | | | |
Warrants for common stock | | | | | 1,240 | | | 1,240 | | | | | |
Total common stock equivalents | | | | | 2,270 | | | 2,087 | | | | | |
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
| | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | |
| 2023 | | 2022 | | | | | | | | |
Options to purchase common stock | 268 | | | 449 | | | | | | | | | |
Restricted stock units | 1,029 | | | 581 | | | | | | | | | |
Warrants for common stock | 1,240 | | | 1,240 | | | | | | | | | |
Total common stock equivalents | 2,537 | | | 2,270 | | | | | | | | | |
15.17. Segment Disclosures
The Company has 2two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.
The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Segment reporting information is as follows:
| | | | EksoHealth | | EksoWorks | | Total |
Three months ended March 31, 2023 | | Three months ended March 31, 2023 | | | | | |
Revenue | | Revenue | $ | 3,997 | | | $ | 125 | | | $ | 4,122 | |
Cost of revenue | | Cost of revenue | 1,951 | | | 171 | | | 2,122 | |
Gross profit | | Gross profit | $ | 2,046 | | | $ | (46) | | | $ | 2,000 | |
| | EksoHealth | | EksoWorks | | Total | | | | | | |
Three months ended March 31, 2022 | Three months ended March 31, 2022 | | | | | | Three months ended March 31, 2022 | | | | | |
Revenue | Revenue | $ | 1,881 | | | $ | 686 | | | $ | 2,567 | | Revenue | $ | 1,881 | | | $ | 686 | | | $ | 2,567 | |
Cost of revenue | Cost of revenue | 1,015 | | | 343 | | | 1,358 | | Cost of revenue | 1,015 | | | 343 | | | 1,358 | |
Gross profit | Gross profit | $ | 866 | | | $ | 343 | | | $ | 1,209 | | Gross profit | $ | 866 | | | $ | 343 | | | $ | 1,209 | |
| Three months ended March 31, 2021 | | | | | | |
Revenue | $ | 1,727 | | | $ | 183 | | | $ | 1,910 | | |
Cost of revenue | 542 | | | 133 | | | 675 | | |
Gross profit | $ | 1,185 | | | $ | 50 | | | $ | 1,235 | | |
Geographically, the regions theThe Company operates in are the following regions: (1) Americas, (2) Europe, the Middle East, and Africa (EMEA), and (3) Asia Pacific (APAC). Individual countries with revenue greater than 10% of total revenue for the three months ended March 31, 2023 and 2022 are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:
| | | | | | | | | | | | | | | | | |
| | | Three Months Ended March 31, |
| | | | | 2022 | | 2021 |
United States | | | | | $ | 1,343 | | | $ | 982 | |
Other | | | | | 55 | | | 36 | |
Americas | | | | | 1,398 | | | 1,018 | |
Germany | | | | | 124 | | | 437 | |
| | | | | | | |
Other | | | | | 440 | | | 186 | |
EMEA | | | | | 564 | | | 623 | |
Japan | | | | | 280 | | | 19 | |
Singapore | | | | | 48 | | | 241 | |
Other | | | | | 277 | | | 9 | |
APAC | | | | | 605 | | | 269 | |
| | | | | $ | 2,567 | | | $ | 1,910 | |
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2023 | | 2022 | | | | |
Americas | | | | | | | |
United States | $ | 2,958 | | $ | 1,343 | | | | |
Other | 4 | | | 55 | | | | | |
Americas | 2,962 | | | 1,398 | | | | | |
| | | | | | | |
EMEA | | | | | | | |
Germany | 244 | | | 124 | | | | | |
| | | | | | | |
| | | | | | | |
Other | 512 | | | 440 | | | | | |
EMEA | 756 | | | 564 | | | | | |
| | | | | | | |
APAC | | | | | | | |
Japan | — | | | 280 | | | | | |
| | | | | | | |
Other | 404 | | | 325 | | | | | |
APAC | 404 | | | 605 | | | | | |
| | | | | | | |
Total Revenue | $ | 4,122 | | | $ | 2,567 | | | | | |
Note. 18 Related Party Transactions
On February 4, 2023, the Company entered into a mutual release and settlement agreement with an entity to settle and resolve any and all potential claims brought forth in connection with a consulting agreement executed between the entity and the Company in July 2017. Under the terms of the consulting agreement, the Company was required to make milestone payments for the introduction of potential partners for, and the consummation of, a strategic joint venture. A member of the Company's board of directors is affiliated with one of two entities under common control.
Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
The Company settled on an amount of $325 to be paid in cash over fourteen months, with combined initial payments of $145 due in the first 40 days and $15 per month for the remaining 12 months.The Company has a liability of $180 and $325 related to this settlement on its consolidated balance sheet as of March 31, 2023 and December 31, 2022, respectively.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
In this Quarterly Report, the “Company”, “we”, “its” and “our” refers to Ekso Bionics Holdings, Inc. and its wholly-owned subsidiaries. The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended March 31, 20222023 (this “Quarterly Report”) and in our Annual Report on Form 10-K for the fiscal year ended December 31, 20212022, which is incorporated herein by reference (the “Annual Report”).
This Quarterly Report contains forward-looking statements. These forward-looking statements include statements other than statements of historical facts contained or incorporated by reference in this Quarterly Report, including statements regarding (i) the plans and objectives of management for future operations, including those relating to the design, development and commercialization of exoskeleton products for humans, (ii) a projectionthe manufacturing of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or otherour products and strengthening our supply chain, and potential opportunities for strategic partnerships, (iii) beliefs regarding the regulatory path for our products, including potential approvals required and timing of approvals, (iv) statements regarding the financial items, (iii)and operational impacts on our business following the completion of the HMC Acquisition, (v) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC, (iv)(vi) our beliefs regarding the potential for commercial opportunities, including for exoskeleton technology in general and our exoskeleton products, in particular, (v)and for strategic partnerships, (vii) our beliefs regarding potential clinical and other health benefits of our medical devices, (viii) the impact and (vi)effects of the COVID-19 pandemic and other risk factors on our business, results of operations or prospects, and (ix) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv) or (v)through (viii) above. The words “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and similar expressions (including the negative of any of the foregoing) are intended to identify forward-looking statements.
The following factors, among others, including those described in the section titled “Risk Factors” included in our Annual Report, as updated and supplemented in this Quarterly Report under the heading “Part II – Item 1A. Risk Factors,” could cause our future results to differ materially from those expressed in the forward-looking information:
•our ability to obtain adequate financing to fund operations and to develop or enhance our technology;
•our ability to generate sufficient cash flow to service our debt obligations;
•our ability to obtain or maintain regulatory approval to market our medical devices;
•our ability to complete clinical trials on a timely basis and that completed clinical trials will be sufficient to support commercialization of our products;
•the anticipated timing, cost and progress of the development and commercialization of new products or services, and improvements to our existing products, and related impacts on our profitability and cash position;
•our ability to effectively market and sell our products and expand our business, both in unit sales and product diversification;
•our ability to achieve broad customer adoption of our products and services;
•existing or increased competition;
•rapid changes in technological solutions available to our markets;
•volatility with our business, including long and variable sales cycles, which could have a negative impact on our results of operations for any given quarter;
•changes to our domestic or international sales and operations;
•our ability to obtain or maintain patent protection for our intellectual property;
•the scope, validity and enforceability of our and third-party intellectual property rights;
•significant government regulation of medical devices and the healthcare industry;
•our ability to receive regulatory clearance from certain government authorities, such as CFIUS (as defined below), including any conditions, limitations or restrictions placed on such approvals;
•our customers’ ability to get third-party reimbursement for our products and services associated with them;them and our ability to manage the complex and lengthy reimbursement process;
•the potential for our products to be subject to voluntary or involuntary recall;
•our product liability insurance may not adequately cover potential claims;
•warrant claims and our accelerated maintenance program results in additional operating costs to us;
•our failure to implement our business plan or strategies;
•our ability to successfully consummate acquisitions on acceptable terms and to integrate any such acquisitions;
•our early termination of leases, difficulty filling vacancies or negotiating improved lease terms;
•our ability to retain or attract key employees;
•scope, scale and duration of the impact of outbreaks of a pandemic disease, such as COVID-19 (coronavirus);COVID-19;
•stock volatility or illiquidity;
•our ability to maintain adequate internal controls over financial reporting;
•the impacts of foreign currency price fluctuations; and
•overall economic and market conditions.
Although we believe that the assumptions underlying the forward-looking statements and forward-looking information contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, such statements and information included in this Quarterly Report may not prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements and forward-looking information included herein, the inclusion of such statements and information should not be regarded as a representation by us or any other person that the results or conditions described in such statements and information or that our objectives and plans will be achieved. Such forward-looking statements speak only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Overview
Our Business
We design, develop, and market exoskeleton products that augment human strength, endurance and mobility. Our exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and by persons with physical disabilities. We have sold or leased devices that (i) enable individuals with neurological conditions affecting gait, including ABI, SCI and SCI,MS, to rehabilitate, and in some cases, to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods.
We believe that the commercial opportunity for exoskeleton technology adoption is accelerating as a result of recent advancements in material technologies, electronic and electrical engineering, control technologies, and sensor and software development. Taken individually, many of these advancements have become ubiquitous in peoples’ everyday lives. We believe that we have learned how to integrate these existing technologies and wrap the result around a human being efficiently, elegantly and safely, supported by an industry leading intellectual property portfolio. We further believe that we can do so across a broad spectrum of applications, from persons with lower limb paralysis to able-bodied users.
EksoHealth
EksoHealth is our business unit focused on developing and marketing exoskeletons for medical applications.
Our leading product in EksoHealth, the EksoNR, is a robotic exoskeleton used to provide physical therapy for patients with lower extremity impairment. EksoNR which in 2019 superseded our EksoGT product in this segment, includes unique features designed specifically to assist physical therapists and other clinicians to teach patients to walk again after suffering a neurological impairment. Typical conditions that can be treated with the assistance of EksoNR include ABIs, such as stroke and traumatic brain injuries, as well as SCIs, MS, and others. The benefits of using EksoNR for rehabilitation can include earlier mobilization of patients, longer and more intense rehab sessions, and betterincreased quality of sessions as compared to alternative therapies. The productEksoNR is most typically used in a clinical setting, with thesettings, most common among those beingcommonly at inpatient rehab facilities and stroke centers.
EksoUE is a wearable upper body exoskeletonEksoHealth expanded its product offerings to include Ekso Indego Therapy and Ekso Indego Personal with the HMC acquisition in the fourth quarter of 2022. The Ekso Indego devices are FDA-cleared lower-limb powered exoskeletons that is also used as a tool during rehabilitation. EksoUE is designedenable task-specific, overground gait training to assist patients with weakness or paralysis in their lower extremities. Ekso Indego Personal, a broad rangelight-weight exoskeleton for safe use in most home and community environments, and Ekso Indego Therapy, an adjustable exoskeleton for patients with spinal cord injury and stroke, address market opportunities across the continuum of upper extremity impairmentscare, particularly within outpatient facilities, complementary to those most typically addressed by the EksoNR, expanding Ekso’s product offering to home and aims to provide them with a wider active range of motion and increased endurance for rehabilitation sessions of higher intensity.community use markets.
EksoWorks
EksoWorks is our business unit focused on developing, marketing, and selling exoskeletons and other assistive tools for industrial applications. The target users for these devices are generally able-bodied, and as such the goal of these products is to reduce fatigue for workers. The benefits of fatigue reduction can include reduced rates of injuries, higher productivity, higher worker morale, and lower turnover. Currently, we primarily sell these products directly to companies that deploy them for use
in their operations.
Within EksoWorks we have two main categories of products. Our EVO, our wearable upper body exoskeleton, products includesupersedes the EksoVest and the new EVO, both of whichas our primary product designed to support the weight of a worker’s arms and tools, reducing the fatigue associated with working at or above shoulder height for extended periods. These products areIn 2022 the EksoWorks unit refocused its product offerings and go to market strategies, placing increased emphasis on EVO and its placement into large industrial settings within our identified target markets. We believe EVO has industrial applications across a broad range of market verticals, and the unit is currently targeted attargeting end markets in aerospace, automotive, manufacturing, commercial construction, and specific construction trades.renewable energy.
Prior to ceasing commercialization of the EksoZeroG is asupport arm and related products and accessories, at the end of the second quarter of 2022, we manufactured and sold our EksoZeroG tool holder, that canwhich could mount on an aerial lift platform or scaffolding. This effectively reduces the weight of heavy tools as felt by the operator. EksoZeroG has been sold primarily through rental companies into the construction market.
First Quarter 20222023 Highlights
•Reported revenue of $2.6 million in the first quarter of 2022
•Achieved gross margins of approximately 47% in the first quarter of 2022
•Booked a total of 23 EksoNR units in the first quarter of 20222023
•Strong cash positionReported revenue of $36.2$4.1 million asin the first quarter of March 31, 2022
2023, an increase of 61% year-over-year
Economic and Industry Trends
Our revenue is highly dependent on market demand for our exoskeleton products. This market demand is influenced by many factors including the level of awareness of robotic exoskeleton rehabilitation among the rehabilitation clinics with significant stroke, ABI, and SCI populations, the imperatives among construction and manufacturing companies to drive adoption of improved safety and health practices, the levels of reimbursements our customers will be able to receive, as well as conditions relating to overall economic growth and general business activity. Difficult and challenging economic conditions, including growing supply chain issues amidst an increasingly inflationary environment, could lead to increased price-based competition. In particular, the effects of such increasing price-based competition may have an especially significant impact on certain products that we offer, including the EksoNR and Ekso Indego, which have a lengthy sale and purchase order cycle because they are major capital expenditure items and generally require the approval of senior management at purchasing institutions. Furthermore, our business includes operations in the Americas, EMEA and APAC, so we are affected by demand for our products in those regions, as well as the strengthening or weakening of local currencies relative to the U.S. Dollar.
The current economic environment is impacting our customers financially and operationally. Hospitals are experiencing staffing shortages and supply chain issues that affect their ability to provide patient care. Additionally, hospitals are facing significant financial pressure as supply chain constraints and inflation drive up operating costs and fiscal stimulus programs enacted during the COVID-19 pandemic wind down. As a consequence of the financial pressures and related public health measuresdecreased profitability, some hospitals have also materially affected how weindicated that they are lowering their capital investment plans and our customers are operating our businesses, and have materially affected our operating results, astightening their operational budgets. We believe that these factors could contribute to a reduced demand for our exoskeleton products decreased as many inpatient rehabilitation facilities temporarily shifted priorities and delayed capital expenditures. While the duration and extent to which this will impact our future results remain uncertain, we have seen certain recoveryofferings, particularly in the demand forUnited States, which may have a material adverse effect on our exoskeleton products following the gradual reopening and recoverybusiness, financial condition, results of the broader global economy, and weoperations, or cash flows.
We believe the clinical need for our products has not diminished, as evidenced by clinical data showing the increased prevalence of strokes during the pandemic. Although concerns about the emergence of new, more infectious variants of the coronavirus remain, we have gradually resumed in-person engagements in additionWe continue to virtual meetingsengage with our current and prospective customers both onsite and virtually through conferences,video conferencing, virtual training events and educationalonline education demos to offer our support and showcase the value of our Ekso devices. Further, now that our clinical teamWhile the impacts of the COVID-19 pandemic are starting to dissipate, it is fully vaccinated and are active onsite at U.S. rehab centers, we expect to see an uptickpossible a resurgence of COVID-19 could result in live in-person interactions going forward. Although market uncertainties related to the pandemic make it difficult for us to project the full impactadverse effects on our business, financial condition, and customers, we believe that we are well-positioned to serve our customers when business conditions begin to normalize.
Throughout the pandemic, our top priority has been to protect the health and safetyresults of our employees and our consumers. We have an optional work from home policy for many of our employees. Vaccinated employees are permitted to workoperations in the office and we have allowed essential business travel to resume. We have also enhanced the use of personal protective equipment in our facilities.
Management continues to actively monitor the global situation, including the geopolitical instability arising out of military conflict and escalating tensions between Russia and Ukraine, and its effects on our financial position and operations.
Management Changes
On January 14, 2022, Jack Peurach, our former President and Chief Executive Officer, notified us of his intention to resign as an officer and member of the Board of Directors of the Company to pursue other endeavors. On January 20, 2022, our Board and Mr. Peurach reached an understanding regarding his decision to leave the Company and entered into an Executive Separation and Release Agreement pursuant to which Mr. Peurach’s last day of service as the President, Chief Executive Officer and as a member of the Company’s Board was January 21, 2022. In addition, our Board of Directors appointed Steven Sherman, who currently serves and previously had served as the Chairman of our Board, to become Chief Executive Officer of the Company effective January 22, 2022. Mr. Sherman continues to serve as the Chairman of the Board of the Company, and Board member Stanley Stern has been designated the Board’s lead independent director. Furthermore, our Board of Directors appointed Scott Davis to become President and Chief Operating Officer effective January 22, 2022.
Finally, on March 4, 2022, William Shaw, our former Chief Commercial Officer, notified our Board of Directors of his intention to resign as Chief Commercial Officer of the Company effective March 11, 2022 in connection with his retention as an employee at another company.future.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Our estimates form the basis for our judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Our most critical accounting estimates include:
•the standalone selling prices used to allocate the contract consideration to the individual performance obligations in our device sales arrangements, which impacts revenue recognition;
•the unobservable inputs and assumptions used by management in estimating the fair value of our warrant liabilities, which impacts net income or loss;
•the valuation of inventory, which impacts gross profit margins; and
•the estimates made regarding the recoverability of our net deferred tax asset, which impacts our financial condition.
Standalone Selling Prices
Our device sales arrangements contain multiple products and services, most often including the device(s) and service, both of which we have identified as distinct performance obligations. Revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling prices considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and gross margin targets. Changes in the relative standalone selling price between devices and service can have an impact on how transaction prices are allocated between revenue and deferred revenue.
Warrant Liabilities
We use the Black-Scholes option-pricing model to value our warrant liabilities at each reporting period, which requires the input of highly subjective assumptions, most notably the estimated volatility of our common stock over the expected term. We use our historical common stock volatility to estimate expected volatility over the warrant terms. Management must also make uncertain estimates regarding the likelihood and timing of certain future events for application of the Lattice Model for the valuation of certain warrants. Changes in these assumptions could have potential material impacts on the estimated fair value of warrant liabilities. During the three months ended March 31, 2023, management made no changes to its estimates regarding the likelihood of future events, but revised its estimates regarding the timing of future events. We do not believe the revision resulted in a material impact to the estimated fair value of warrant liabilities measured using the Lattice Model.
Inventory Valuation
Inventory is stated at the lower of cost or net realizable value. Cost is computed using the standard cost method which approximates actual cost on a first-in, first-out basis. The cost basis of our inventory is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than those projected by management, additional inventory write-downs may be required, which could have a material adverse effect on the results of our operations.
Deferred Tax Asset
We estimate a valuation allowance in consideration of the realizability of our net deferred tax assets, primarily based on our assessment of the timing, likelihood and amounts of potential future income during which such items become deductible. It is inherently difficult and subjective to estimate such amounts, as we must determine the probability of various possible outcomes and estimate future amounts. Management does not believe it is more likely than not that we will generate future income in a timeframe and amount sufficient to realize our net deferred tax assets. Changes in management's estimate of future income in the timeframe during which the temporary differences and carryforwards comprising our deferred tax assets become deductible could result in a material impact to our financial position including the recognition of a net deferred tax asset.
Accounting Policies
An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimate that are reasonably likely to occur, could materially impact the condensed consolidated financial statements. We believe that our critical accounting policies reflect the more significant estimates and assumptions used in the preparation of the condensed consolidated financial statements. Refer to Note. 2 Basis of Presentation and Summary of Significant Accounting Policies and Estimates in the notes to our condensed consolidated financial statements.statements included elsewhere in this Quarterly Report on Form 10-Q.
Results of Operations
The following table presents our results of operations for the three months ended March 31, 2023 and 2022 (in thousands, except percentages): | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended March 31, | | | | |
| 2022 | | 2021 | | Change | | % Change |
| | | | | | | |
Revenue | $ | 2,567 | | | $ | 1,910 | | | $ | 657 | | | 34 | % |
Cost of Revenue | 1,358 | | | 675 | | | 683 | | | 101 | % |
Gross profit | 1,209 | | | 1,235 | | | (26) | | | (2) | % |
Gross profit % | 47 | % | | 65 | % | | | | |
| | | | | | | |
Operating expenses: | | | | | | | |
Sales and marketing | 1,629 | | | 1,793 | | | (164) | | | (9) | % |
Research and development | 999 | | | 603 | | | 396 | | | 66 | % |
General and administrative | 2,818 | | | 1,978 | | | 840 | | | 42 | % |
| | | | | | | |
Total operating expenses | 5,446 | | | 4,374 | | | 1,072 | | | 25 | % |
Loss from operations | (4,237) | | | (3,139) | | | (1,098) | | | 35 | % |
Other expense, net: | | | | | | | |
Interest expense | (27) | | | (26) | | | (1) | | | 4 | % |
(Loss) gain on revaluation of warrant liabilities | (100) | | | 11 | | | (111) | | | n/m(1) |
| | | | | | | |
| | | | | | | |
Other expense, net | (256) | | | (516) | | | 260 | | | (50) | % |
Total other expense, net | (383) | | | (531) | | | 148 | | | (28) | % |
Net loss | $ | (4,620) | | | $ | (3,670) | | | $ | (950) | | | 26 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | | | |
| 2023 | | 2022 | | Change | | % Change |
| | | | | | | |
Revenue | $ | 4,122 | | | $ | 2,567 | | | $ | 1,555 | | | 61 | % |
Cost of revenue | 2,122 | | | 1,358 | | | 764 | | | 56 | % |
Gross profit | 2,000 | | | 1,209 | | | 791 | | | 65 | % |
Gross profit % | 49 | % | | 47 | % | | | | |
| | | | | | | |
Operating expenses: | | | | | | | |
Sales and marketing | 2,088 | | | 1,629 | | | 459 | | | 28 | % |
Research and development | 1,154 | | | 921 | | | 233 | | | 25 | % |
General and administrative | 3,206 | | | 2,896 | | | 310 | | | 11 | % |
| | | | | | | |
Total operating expenses | 6,448 | | | 5,446 | | | 1,002 | | | 18 | % |
Loss from operations | (4,448) | | | (4,237) | | | (211) | | | 5 | % |
Other (expense) income, net: | | | | | | | |
Interest expense | (127) | | | (27) | | | (100) | | | 370 | % |
Loss on revaluation of warrant liabilities | (26) | | | (100) | | | 74 | | | n/m(1) |
| | | | | | | |
| | | | | | | |
Unrealized gain (loss) on foreign exchange | 217 | | | (254) | | | 471 | | | n/m(1) |
Other expense, net | (5) | | | (2) | | | (3) | | | n/m(1) |
Total other (expense) income, net | 59 | | | (383) | | | 442 | | | (115) | % |
Net loss | $ | (4,389) | | | $ | (4,620) | | | $ | 231 | | | (5) | % |
(1)Not meaningfulMeaningful
Revenue
Revenue increased $0.7$1.6 million, or 34%61%, for the three months ended March 31, 2022,2023, compared to the same period of 2021. Revenue in the first quarter2022. This increase was comprised of 2022 included approximately $1.9a $2.1 million increase in EksoHealth revenue, and approximately $0.7partially offset by a $0.6 million decrease in EksoWorks revenue. EksoWorks.
The increase in EksoHealth revenue was primarily driven by an increase in the volume of EVO vest salesEksoNR device sales. The decrease in EksoWorks revenue was primarily driven by a reduction in the EksoWorks business unitvolume of EVO and EksoVest sales and the absence of the recognition of prepaid royalties associated with a license and distribution agreement that expired.
Gross Profit
Gross profit decreased 2% for the three months ended March 31, 2022 compared toin the same period of 2021.Gross margin2022, which was approximately 47% for the three months ended March 31, 2022, compared to a gross margin of 65% for the same period in 2021. The overall decrease in gross margin was primarily due to the increase in EksoHealth service costs, changes in product mix and increases in inventory costs due to the continued supply shortage; partially offset by the recognition of royalty revenue associated with a license and distribution agreement that expired.
Gross Profit
Gross profit increased $0.8 million for the three months ended March 31, 2023 compared to the same period of 2022, driven by an increase in sales in the EksoHealth segment.
EksoHealth service costsGross margin increased to 49% for the three months ended March 31, 2023, compared to a gross margin of 47% for the same period of 2022. The overall increase in gross margin was primarily due to increased headcount and the company providing service on an increased number of customer units, owing to the receipt of service parts during the quarter, the shortage of which had previously precluded the completion of service.lower device costs.
Operating Expenses
Sales and marketing expenses decreased $0.2increased $0.5 million, or 9%28%, for the three months ended March 31, 2022,2023, compared to the same period of 2021.2022. The decreaseincrease was primarily due to reduced generalthe addition of headcount associated with the acquisition of HMC and an increase in marketing activities.
Research and development expenses increased $0.4$0.2 million, or 66%25%, for the three months ended March 31, 2022,2023, compared to the same period of 2021,2022. The increase was primarily due to an increase in product development activitythe addition of headcount and headcount.costs associated with the acquisition of HMC
General and administrative expenses increased $0.8$0.3 million, or 42%11%, for the three months ended March 31, 2022,2023, compared to the same period of 2021,2022, primarily due to an increase in compensationHMC related audit and integration costs associated withoffset by the appointmentabsence of our new Chief Operating Officer and noncash stock-based compensation related to the appointment of our new Chief Executive Officer, as well as severance expensecosts associated with the departure of our former Chief Executive Officer.Officer in the same period of 2022.
Total Other Expense,(Expense) Income, Net
Loss on revaluation of warrant liabilities was $0.1 millionde minimis for the three months ended March 31, 2022,2023, and was associated with the revaluation of warrants issued in 2019, 2020 and 2021. GainLoss on warrant liabilities was de minimis$0.1 million for the three months ended March 31, 2021,2022, and was associated with the revaluation of warrants issued in 2019, 2020 and 2021. Gains and losses on revaluation of warrants are primarily driven by changes in our stock price and changes to the risk freerisk-free rate.
Other expense, netUnrealized gain on foreign exchange for the three months ended March 31, 20222023 was $0.3$0.2 million as compared to $0.5an unrealized loss on foreign exchange of $0.3 million for the same period of 2021, due to2022. These unrealized gains and losses onare primarily the result of foreign currency revaluations of our inter-company monetary assets and liabilities.
Financial Condition, Liquidity and Capital Resources
Since our inception, we have devoted substantially all of our efforts toward the development and commercialization of exoskeletons for the medical and industrial markets toward the commercialization of medical exoskeletons to rehabilitation centers and toward raising capital. We have financed our operations primarily through the issuance and sale of equity securities for cash consideration and through bank debt.
Liquidity and Capital Resources
On March 31, 2022,2023, we had working capital of $37.2$18.1 million, compared to working capital of $40.9$21.8 million at December 31, 2021.2022. The decrease in working capital iswas primarily due to a lower cash balance from cash used in operations. Our cash as of March 31, 2022,2023, consisted of bank deposits with third party financial institutions. As of March 31, 2022,2023, of our $36.2$16.3 million of cash, $35.5$15.3 million was held domestically while $0.7$1.0 million was held by foreign subsidiaries.
As described in Note 810 in the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q under the caption Notes Payable, net, borrowings under our new secured term loan agreement with Pacific Western Bank have a requirement of minimum cash on hand equivalent to the current outstanding principal balance. As of March 31, 2022,2023, $2.0 million of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of March 31, 20222023 is estimated to be $34.2approximately $14.3 million. With this unrestricted cash balance, we believe that we currently have sufficient cash to fund our operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.
Cash
The following table summarizes the sources and uses of cash (in thousands).
| | | Three months ended March 31, | | Three months ended March 31, |
| | 2022 | | 2021 | | 2023 | | 2022 |
Net cash used in operating activities | Net cash used in operating activities | $ | (4,206) | | | $ | (2,000) | | Net cash used in operating activities | $ | (4,214) | | | $ | (4,206) | |
Net cash used in investing activities | | Net cash used in investing activities | (42) | | | — | |
| Net cash provided by financing activities | — | | | 38,712 | | |
Effect of exchange rate changes on cash | Effect of exchange rate changes on cash | (24) | | | (35) | | Effect of exchange rate changes on cash | 8 | | | (24) | |
Net (decrease) increase in cash | (4,230) | | | 36,677 | | |
Net decrease in cash | | Net decrease in cash | (4,248) | | | (4,230) | |
Cash at the beginning of the period | Cash at the beginning of the period | 40,406 | | | 12,862 | | Cash at the beginning of the period | 20,525 | | | 40,406 | |
Cash at the end of the period | Cash at the end of the period | $ | 36,176 | | | $ | 49,539 | | Cash at the end of the period | $ | 16,277 | | | $ | 36,176 | |
Net Cash Used in Operating Activities
Net cash used in operations increased $2.2 million, or 110%0%, for the three months ended March 31, 2022,2023, compared to the same period of 20212022 was primarily due to higher payments forof acquisition and integration costs associated with HMC, offset by payments of business development costs incurred in late 2021, increased employee compensation related to higher headcount and increased inventory purchases.2021.
Net Cash Used in Investing Activities
Net Cash Provided by Financing Activities
Net cash provided by financingused in investing activities of $38.7 million for the three months ended March 31, 2021,2023, was related to leasehold improvements for our new headquarters and manufacturing facility in San Rafael, California.
Material Cash Requirements
Our material cash requirements include the following items, some of which are represented in the table of Contractual Obligations and Commitments: (1) employee wages, benefits and incentives, (2) the procurement of raw materials and components to support the manufacturing and sale of our products, (3) expenditures for the ongoing improvement and development of existing and new technologies, (4) debt repayments (for additional information see Note 10 in the notes to our condensed consolidated financial statements included elsewhere in the Quarterly Report on Form 10-Q), and (5) operating lease payments (for additional information see Note 11 in the notes to our condensed consolidated financial statements included elsewhere in the Quarterly Report on Form 10-Q).
We expect that our operating cash requirements in the near term will continue to exceed cash provided by operations with the additional headcount and product development activities assumed in the HMC Acquisition. Additionally, our term loan with Pacific Western Bank will mature in August 2023 requiring cash outflows of $2.0 million for the repayment of principal. Principal payments on our promissory note with Parker Hannifin begin in December 2023. Notwithstanding our ability to refinance our maturing loan obligation, coordinate with our suppliers to delay the receipt of materials on order, or delay product development activities, with cash on hand of $16.3 million at March 31, 2023 we have sufficient resources to finance our operations until the first quarter of 2024. However, as described in Note. 1 of the notes to our condensed consolidated financial statements management believes our plans are sufficient to alleviate the substantial doubt raised at March 31, 2023 about our ability to meet cash requirements twelve months from the saleissuance of the financial statements which is in the second quarter of 2024.
The Company does not expect, nor do our historical operating results suggest, that cash flows generated from operations will be sufficient to meet our material cash requirements in the long term. Management expects that the Company's historical reliance on external financing, from both equity and debt financings, will continue to provide the capital necessary to meet its material cash requirements in the long term. Management has not yet determined the form such additional financing may take, but management expects that the most likely forms include one or more of the following: (i) underwritten offerings of shares of our common stock (ii) sales of shares of our common stock under an "at the market" offering program, (iii) incurring indebtedness with one or more financial institutions, and warrants for net proceeds(iv) the factoring of $36.5 million in connection with the equity financing, net proceeds of $0.7 million from our “at the market offering” program, and proceeds of $1.4 million from the exercise of warrants. There was no comparable amount for the three months ended March 31, 2022.trade receivables.
Contractual Obligations and Commitments
The following table summarizes our outstanding contractual obligations as of March 31, 2022,2023, and the effect those obligations are expected to have on our liquidity and cash flows in future periods (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Payments Due By Period: |
| Total | | Less than One Year | | 1-3 Years | | 3-5 Years | | After 5 Years |
Note payable, principal and interest | $ | 2,128 | | | $ | 90 | | | $ | 2,038 | | | $ | — | | | $ | — | |
Facility operating leases | 325 | | | 162 | | | 144 | | | 19 | | | — | |
Purchase obligations | 3,460 | | | 3,393 | | | 67 | | | — | | | — | |
Total | $ | 5,913 | | | $ | 3,645 | | | $ | 2,249 | | | $ | 19 | | | $ | — | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Payments Due By Period: |
| Total | | Less than One Year | | 1-3 Years | | 3-5 Years | | |
Term loan | $ | 2,067 | | | $ | 2,067 | | | $ | — | | | $ | — | | | |
Promissory note | 5,000 | | | 625 | | | 2,500 | | | 1,875 | | | |
Facility operating leases | 1,480 | | | 412 | | | 813 | | | 255 | | | |
Purchase obligations | 3,800 | | | 3,800 | | | — | | | — | | | |
Total | $ | 12,347 | | | $ | 6,904 | | | $ | 3,313 | | | $ | 2,130 | | | |
In response to, or in anticipation of, supplier disruptions and extended lead times, we may stockpile certain components or raw materials to help prevent disruption in our production of the EksoNR, and Ekso Indego Therapy and Ekso Indego Personal devices. Such purchasing behavior is a contributing factor to the increase in purchase obligations as compared to prior periods. These actions have, and could continue to have, a short-term adverse impact on our cash used in operating activities and increase our inventory balance. Obligations related to these activities are reflected in the line purchase obligations in the table above.
Refer to Note 13. 15. Commitments and Contingencies in the notes to our condensed consolidated financial statements for additional information regarding our license agreementscontractual obligations, and purchase obligations.lease commitments.
Item 3. Quantitative and Qualitative Disclosure About Market Risk
We are exposedThere have been no material changes in our market risk during the three months ended March 31, 2023, compared to market risksthe disclosures in the ordinary coursePart II, Item 7A of our business, including inflation risks.
We do not believe that inflation has had a material effectAnnual Report on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.
In addition, we conduct business in foreign countries and have subsidiaries based in Germany and Singapore. Accordingly, we are exposed to exchange rate risk. See Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our Annual Report.Form 10-K for the year ended December 31, 2022.
Item 4. Controls and Procedures
Disclosure Controls and Procedures.
Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, as amended (“Exchange Act”)) as of the end of the period covered by this Quarterly Report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
It should be noted that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment and makes assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. Management believes that the financial statements included in this Quarterly Report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
WeFrom time to time we are subject to legal proceedings and claims arising in the ordinary course of business. Based on our current knowledge, we believe that the amount or range of reasonably possible losses will not, either individually or in the subject of any pending legal proceedings; and to the best of our management’s knowledge, no such proceeding is presently threatened, the results of which wouldaggregate, have a material impactadverse effect on the Companies properties,our business, results of operations, or financial condition. Further, to
The results of any litigation cannot be predicted with certainty, and an unfavorable resolution in any legal proceedings could materially affect our future business, results of operations, or financial condition. Regardless of the knowledgeoutcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management no director or executive officer is partyresources, and other factors. For additional information, please refer to any actionNote 13. Commitments and Contingencies in which any has an interest adversethe notes to us.our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Item 1A. Risk Factors
We have not identified any material changes to the risk factors previously disclosed in Part I - Item 1A - “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.2022.
Item 6. Exhibits
| | | | | | | | | | | | | | |
Exhibit Number | | Description | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
| | | |
| | | | |
101* | | The following financial statements from the Ekso Bionics Holdings, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2022,2023, formatted in Extensible Business Reporting Language (“XBRL”): | |
| | • | unaudited condensed consolidated balance sheets; | |
| | • | unaudited condensed consolidated statements of operations and comprehensive income (loss); | |
| | • | unaudited condensed consolidated statements of stockholders’ equity; | |
| | • | unaudited condensed consolidated statement of cash flows; and | |
| | • | notes to unaudited condensed consolidated financial statements. | |
| | | | | | | | |
| * | Filed herewith. |
| #+ | Indicates management compensatory plan or other agreement.Furnished herewith. |
| | |
| | |
| | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Ekso Bionics Holdings, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | |
| EKSO BIONICS HOLDINGS, INC. |
| |
Date: April 28, 202227, 2023 | By: | /s/ Steven ShermanScott G. Davis |
| | Steven ShermanScott G. Davis |
| | Chief Executive Officer and Chairman |
| | (Duly Authorized Officer and Principal Executive Officer) |
| | |
Date: April 28, 202227, 2023 | By: | /s/ John F. GlennJerome Wong |
| | John F. GlennJerome Wong |
| | Chief Financial Officer |
| | (Principal Financial and Accounting Officer) |
| | (Duly Authorized Officer and Principal Financial and Accounting Officer) |